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Part I: p53 functions as a negative regulator of osteoblastogenesis, 
osteoblast-dependent osteoclastogenesis and bone remodeling. 
Summary: 
 p53 is a well known tumor suppressor and it is mutated in more than half of 
primary human tumors (Levine et al., 1991). p53 is critical in safeguarding against cancer 
development mainly by activating or repressing target genes involved in cell cycle arrest, 
programmed cell death, and cell senescence (Rich et al., 2000). Here I report an 
additional role for p53 in mouse development. I show that p53 also regulates osteoblast 
differentiation, bone formation and osteoblast-dependent osteoclast differentiation.  
 p53-/- mice displayed osteosclerotic phenotypes, characterized by a high bone 
mass, especially at trabecular bones. Both bone formation and bone resorption rates were 
increased. My studies reveal that p53 negatively regulate bone formation by inhibiting 
osteoblast activity. p53-/- osteoblasts show accelerated differentiation and proliferation, 
two cellular events believed to be mutually exclusive. Reconstitution of p53 in p53-/- 
osteoblasts reinstated the defect. Furthermore, mechanistic study of p53-/- mice and 
osteoblasts suggested that the enhanced osteoblast differentiation is secondary to an 
increase in expression of osterix as a result. This lineage specific transcription factor 
osterix was known to be essential in osteoblast differentiation (Nakashima et al., 2002). 
Ectopic expression of osterix could mediate the enhanced differentiation of p53-/- 
osteoblasts. Further reporter assays indicate that p53 represses osterix transcription by the 
minimal promoter in a DNA-binding independent manner. Since the biological 
significance in most cases of p53 mediated repression remains unclear, osterix may serve 
as a model to study p53 repression. 
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 On the other hand, while p53 has no effect on osteoclast differentiation and 
resorption per se, p53-/- osteoblasts exhibited elevated osteoclastogenic activities. In 
addition, the enhanced ability of p53-/- osteoblasts to support osteoclast differentiation is 
associated with an increase in expression of M-CSF. Further studies revealed that M-
CSF, a cytokine essential for osteoclastogenesis, is under the control of osterix. 
Accordingly, a net result of increased bone formation and resorption is osteosclerosis in 
p53-/- mice. Hence, p53-/- mice may provide a model to study p53 in bone remodeling and 
the coupling between osteoblasts and osteoclasts.  
 Furthermore, inactivation of p53 is sufficient to rescue the osteoblast 
differentiation defects observed in mice lacking c-Abl, a p53 interacting protein. I have 
previously established c-Abl mice as a model for senile osteoporosis (Li et al., 2000). As 
p53 expression is regulated during osteoblast differentiation in addition to genotoxic and 
other stresses, I postulate that p53 may serve as a differentiation checkpoint for 
osteoblasts. Thus these results identify p53 as a novel regulator of osteoblast 




                                                                                                               Summary         VII 
 4
Part II: c-Abl regulates Atm- and Atr-dependent DNA damage response: 
evidence for a feedback loop between Atm and c-Abl  
Summary:                  
 In addition to c-Abl’s role in osteoblast differentiation and bone remodeling, the 
c-Abl proto-oncogene encodes a non-receptor tyrosine kinase, whose physiological 
function is still elusive (Li, 2005). Its oncogenic form BCR-ABL, is the leading cause of 
human chronic myeloid leukemia, a proliferative disorder of hematopoietic stem cells 
(Gale and Butturini, 1993). c-Abl is activated by DNA damage in an ATM dependent 
manner (Foray et al., 2002). The current view is that c-Abl relays pro-apoptotic signals 
from Atm to p73/p53 (Dobbelstein et al., 2005). Accumulating evidence also suggests 
that c-Abl is involved in genotoxic stress response, actin dynamics, and mitogenesis 
(Kharbanda et al., 1997). 
 It remains controversial whether c-Abl has a function in DNA damage induced 
cell cycle control and in DNA repair. Here I provide evidence that c-Abl acts at a novel 
step that affects most cellular events in DNA damage response.   
 Nuclear foci are centers of DNA repair and of signal propagation to control cell 
cycle arrest or programmed cell death (Fernandez-Capetillo et al., 2003). My studies 
reveal that foci assembly of mediators TopBP1, Brca1, 53BP1 and Rad51 was altered in 
c-Abl deficient MEFs. Although c-Abl itself was not found on nuclear foci, these 
mediators assembled to the nuclear foci and are believed to present Chk1/Chk2 to Atm 
and Atr and facilitate the phosphorylation (Anderson et al., 2001). Further studies 
revealed that foci assembly of earlier proteins H2AX, MRE11, ATM/ATR were not 
altered in c-Abl-/- MEFs, suggesting that c-Abl plays at a later step after ATM/ATR 
assembly. 
                                                                                                               Summary         VII 
 5
Indeed, I found diminished activation of transducers Chk1/Chk2 in c-Abl-/- MEFs. p53 
phosphorylation at Ser15 is known to be a major effector molecule downstream of 
Atm/Atr in DNA damage response. This activation of p53 was also diminished in c-Abl 
deficient cells. Three p53 target genes were also affected by c-Abl deficiency. They are 
p21, 14-3-3б and Gadd45 and are cell cycle regulators (Levine et al., 1991). Further 
studies with drugs that specifically activate the ATM or the ATR pathway revealed that 
c-Abl acted upstream of both ATM/ATR signaling cascades in response to DSBs and 
ssDNA. The findings were confirmed by c-Abl reconstitution and c-Abl inhibition with 
STI571. Overall, these results suggest that c-Abl participates in DNA damage response in 
a kinase dependent manner. The key experiments were further verified with c-Abl-/- 
osteoblasts, in which c-Abl plays important roles in differentiation and in oxidative stress 
response.  
 Therefore, c-Abl-/- MEFs showed defects in nuclear foci assembly of proteins such 
as TopBP1, Brca1, 53BP1 and Rad51, activation of both Chk2 and Chk1, 
phosphorylation of p53 at Ser15 and induction of p53 target genes. Moreover, I found 
that c-Abl deficiency led to defects in cell cycle checkpoint control and DNA repair, 
especially in repair of single stranded DNA breaks. Hence, I reveal a novel role for c-Abl 
in Atr-dependent DNA damage response as it controls activation of both Atm and Atr.  
Furthermore, I propose a feedback loop in which Atm activated c-Abl supports proper 
nuclear foci formation and Atm/Atr activation to regulate cell cycle control and DNA 
repair. These findings advance our understanding of DNA damage response and c-Abl 
function. 
                                                                                     Chapter 1-Introduction Part I; c-Abl 
 6
 Chapter 1: Introduction 
PART I: c-Abl 
I. 1.1 History 
c-Abl (Abelson Tyrosine Kinase) was identified as the cellular homologue of v-
Abl (viral-Abl), an Abelson Murine Leukemia Viral oncogene (A-MuLV) (Kerr et al., 
1994; Wang and Baltimore, 1983). The gene ABL1 encodes a 150kDa (kilo-Dalton) 
protein, also known as p150, which is a member of the non-receptor tyrosine kinase 
family and its activity is tightly controlled in vivo (Wang, 1993). The importance of 
studying this protein comes from its structural alikeness to BCR-ABL, the leading cause 
of human Chronic Myeloid Leukemia (CML); and also because c-Abl is an essential gene 
in mouse development (Ren, 2005; Sattler et al., 1996; Saglio and Cilloni, 2004).   
I. 1.2 c-Abl isoforms and family members 
c-Abl is ubiquitously expressed in all cell types tested and during all stages of 
development (Chung and Wong, 1995). The protein is conserved through metazoan 
evolution and has now been cloned in various organisms from nematode to human 
(Ramakrishnan and Rosenberg, 1989). There are two predominant isoforms of c-ABL, 
type 1a and 1b in humans (Hernandez et al., 2004). They are generated from two 
messenger RNAs (mRNAs) as either a 6- or 7-kb transcript from the ABL1 gene. This is a 
result of differential splicing of the first exon joining to the common exons 2-11. In 
mouse, there are also two major c-Abl isoforms, type I and type IV (Lu and Osmond, 
2000). The type IV c-Abl mRNA is rather constant in expression levels, while the type I 
mRNA level varies greatly in different mouse tissues (Collins et al., 1986; Shaul, 2000; 
Tybulewicz et al., 1991).  
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c-Abl is a member of the Src family of non-receptor tyrosine kinases (NRTK), 
sharing common features of functional domains with c-Src. c-Abl resembles Src in the 
amino terminus that contains the SH3, SH2 and the kinase domains, but it differs by 
having a large C-terminal domain of about 60 kiloDalton (kD) (Mohammadi et al., 1997; 
Parrizas et al., 1997) (Illustration 1). c-Abl has three family derivatives: 1) BCR-ABL, a 
oncogenic form that is implicated in human CML development; 2) v-ABL, a fusion 
protein of MuLV gag and c-Abl that can transform cells; and 3) TEL-ABL, a fusion 
protein between TEL and c-ABL that is implicated in hematopoietic transformation. In 
addition, c-Abl also has a paralogue, Abl-Related Gene (ARG) (Druker et al., 2001). ARG 
encodes a non-receptor tyrosine kinase on the opposite branch of the duplicated c-Abl 
gene family. Like c-Abl, ARG is also widely expressed and it shares substantial sequence 
similarity with c-Abl in SH3, SH2 and the kinase domains (Bianchi et al., 2002; Wang 
and Kruh, 1996).  
I. 1.3 Structure and localization of c-Abl  
c-Abl has a myristoylation site at the extreme N-terminus. This myristoylation is 
found in human 1b isoform and mouse IV isoform. It functions in helping the protein to 
transiently localize onto the plasma membrane and is critical for c-Abl activation. 
Following the N-myristoylation group, c-Abl has a Src homology 3 (SH3) and 2 (SH2) 
domains. SH3 domain is involved in protein-protein interactions while SH2 domain is 
involved in interaction with phospho-tyrosine residues (Feller et al., 1994). Following a 
short linker, the c-Abl kinase domain resides from amino acid 242 to 493. This domain 
enables the protein to tyrosine phosphorylate more than 15 proteins, such as Bruton's 
tyrosine kinase, RAD52, p73 and Cyclin dependent kinase 5 (Cdk5). At the C- terminus 
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of c-Abl, there are three nuclear localization signals (NLS) and one nuclear export signal 
(NES). These signals allow c-Abl to continuously shuttle between the nucleus and the 
cytoplasm (Allen and Wiedemann, 1996; Djordjevic and Driscoll, 2002).   In addition, c-
Abl has a long C-terminus that contains a putative actin-binding domain and a DNA 















Illustration 1: The picture extracted from (Hantschel et al., 2004) shows a schematic 
diagram of the structures of c-Abl isoforms, derivatives and related Src and Tec families.   
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 I.2 BCR-ABL, CML and Gleevec 
CML 
CML occurs mainly in adults. A very small number of children also develop this 
disease (Perrotti et al., 2003). Other types of leukemia may develop in different 
populations: Acute lymphocytic leukemia (ALL) is the most common type of leukemia in 
young children; Acute myeloid leukemia (AML) occurs in both adults and children; and 
Chronic lymphocytic leukemia (CLL) most often affects adults over the age of 55. About 
4,600 new cases of CML are diagnosed each year in the United States and it is 
distinguished from other types of leukemia by the presence of a genetic abnormality in 
DNA of the blood cells, called the Philadelphia chromosome (Martiat et al., 1991; 




The cytogenetic marker, t (9; 22) (q34; q11) Philadelphia (Ph) chromosome, is a 
specific chromosomal abnormality, resulting in an exchange of the genetic material 
between the long arms of chromosomes 9 and 22. This brings together two genes: the 
BCR (breakpoint cluster region) gene on chromosome 22 and the ABL gene on 
chromosome 9, leading to the generation of the Philadelphia chromosome (Ph-
chromosome), and the expression of the p210BCR-ABL oncoprotein that is constitutively 
active as a tyrosine kinase (Ren, 2005). The protein activates multiple signal transduction 
pathways, leading to uncontrolled cell growth and is responsible for approximately 90% 
of adult CML, 20% of adult ALL and 2% of adult AML (Kurzrock et al., 1987).  
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Gleevec 
Recently, Gleevec (Imatinib Mesylate or STI571), a small molecule, has been 
developed as an inhibitor of BCR-ABL and a therapy of CML (Druker, 2002). It has an 
extremely high specificity for c-Abl and is proven clinically very effective in treating 
BCR-ABL caused CML (La Rosee et al., 2002). This small molecule binds to the ATP-
binding pocket of c-Abl and causes a conformational change such that the tyrosine kinase 
domain is inactivated (the activation loop is turned into an inactive, non-phosphorylated 
conformation) (Heinrich et al., 2000; Druker et al., 2001). Of course, the powerful drug 
has its loopholes; it is not effective in treating patients at the blastic stage of CML and 
some chronic phase patients.  The resistance is mainly caused by mutations in BCR-ABL 
that compromised the binding of Gleevec to BCR-ABL (Kantarjian et al., 2002; 
Hofmann et al., 2002). Furthermore, the rapid approval of Gleevec means that there are 
insufficient studies on the drug’s long-term side effects. Thus, more efforts are called for 
to study c-Abl and related proteins in order to develop more powerful and less toxic 
drugs for CML treatment.  
I.3 Activation of c-Abl  
c-Abl exists as an inactive protein under normal conditions. Experiments using a 
SH3 interacting protein regulatory factor X 1 (RFX1) revealed that c-Abl is innately 
inactive and this is an intrinsic property that does not require an endogenous inhibitor. 
Structural studies suggest that SH3-SH2 domains form a clamp that interacts with the 
kinase domain of c-Abl to inhibit its kinase activity.  On the other hand, c-Abl interacting 
proteins have been identified that regulate the kinase activity of c-Abl.  For example, the 
antioxidant protein PAG (Msp23 or Prx1, peroxiredoxin I) binds to the SH3 domain and 
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specifically suppresses c-Abl tyrosine kinase activity upon co-expression in vivo (Wen et 
al., 1997). Other binding partners that were known to inhibit c-Abl activity include 
Wiskott-Aldrich syndrome protein (WASP), Rb, F-actin and Phosphatidylinositol-4,5-
bisphosphate (PtdIns(4,5)P2)  (Lanier and Gertler, 2000).   
c-Abl could become activated in response to numerous extra- and intra-cellular 
stimuli, namely: oxidative stress, DNA damage, growth factors and other kinases or 
proteins.  This activation is assisted by cellular proteins that interact with c-Abl (Bowen 
et al., 2002). For example, when cells are exposed to ionizing radiation (IR), ATM is 
activated and phosphorylates nuclear c-Abl and causes it to bind to p53 in an ATM-
dependent manner (Li et al., 2004). c-Abl is then capable of activating downstream 
cellular events.  
I.4 Interacting proteins of c-Abl  
c-Abl contains binding sites for a large pool of cellular proteins. Many of these 
interacting proteins also regulate the activity of c-Abl (Table 1). In order to better 
understand the function of c-Abl, more c-Abl interacting proteins are uncovered by 
glutathione S-transferase (GST)-pull down and yeast two-hybrid experiments. I have 
identified TopBP1 as an interacting protein of c-Abl by the GST-Abl pull-down 
experiment (Zeng et al., 2005). TopBP1 is found to physically interact with c-Abl in vivo 
and in vitro and regulates c-Abl in a feedback loop. Other proteins that are reported to 
interact with c-Abl and are involved in DNA damage include Rad51, Brca1, DNA-PK, 
WRN, and ATM (Shaul and Yehoyada, 2005).  
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Name Interacting domain of c-Abl Experiment type Activation/Inhibition
Retinoblastoma 1 kinase domain-N lobe in vitro Inhibition 
PAG/Msp23/Prx1 SH3 and kinase in vivo; in vitro; yeast 2 hybrid  Inhibition 
Crk proline rich in vivo; in vitro Activation 
Regulatory factor X 1 SH3 in vivo; in vitro Activation 
ATM SH3 in vivo; in vitro; yeast 2 hybrid Activation 
F-actin Actin binding domain in vivo; in vitro Inhibition 
Ras inhibitor 1 SH2-SH3 in vitro Activation 
 
Table 1. The list is some proteins that are known to interact directly with c-Abl and 
regulate c-Abl activity. Their interactions could be demonstrated in vivo, in vitro or by 
yeast 2 hybrid system (Wang, 2004).  
 
I.5 Cellular functions of c-Abl  
Active c-Abl has been implicated in tumorigenesis and in many cellular processes 
including differentiation, cell division, adhesion, DNA damage-induced apoptosis, 
senescence, integrin stimulation, cellular stress responses and in growth factor receptor 
signaling (Kharbanda et al., 1998). One of the intensively studied roles of c-Abl is in cell 
response to IR that causes DNA double stranded breaks (Wang, 2000). After activation 
by ATM, active c-Abl in the nucleus promotes apoptosis via phosphorylating and 
destabilizing p73. c-Abl is rapidly degraded after activation but exactly how the 
degradation is regulated remains to be solved.   
In addition to its vital roles in apoptosis and cell proliferation, c-Abl also interacts 
with and modifies many important proteins involved in DNA replication, recombination 
and repair. c-Abl also has a DNA-binding domain that allows it to bind to the minor 
groove of the DNA double helix (Ren et al., 1994). It can also bind with deformed DNA 
structures like the four-way junctions, and the single-stranded loop of bubble DNA 
arising from a string of mismatches, which may form intra-strand crosslinks (David-
Cordonnier et al., 1998). The binding to intra-strand crosslinks caused by genotoxic 
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stress also suggests a possible role for c-Abl in DNA recombination and repair. The study 
of cellular functions of c-Abl is complicated by the fact that c-Abl plays different roles in 
nuclear and cytoplasmic compartments (Zhu and Wang, 2004).  
I.6 Roles of c-Abl in development 
c-Abl proto-oncogene has been reported to be expressed widely throughout 
murine gestation.  It is also found that the expression of c-Abl is the highest in thymus, 
spleen, and testes, even though it is ubiquitously expressed in most adult mouse tissues 
(Schwartzberg et al., 1991). To examine the physiologic function of c-Abl, c-Abl gene 
was disrupted in mouse embryonic stem cells to generate a mouse strain carrying the c-
Abl null mutation (Chung and Wong, 1995). Most mice homozygous for c-Abl show 
runtedness, neonatal lethality (died 1 to 2 weeks after birth), reduced fertility and 
morphological abnormalities such as foreshortened crania. These mice are also more 
susceptible to infections, accompanied by reductions in pro-B and pre-B cells in the bone 
marrow.  Many adult mice showed T and B cell lymphopenia as well as thymic and 
splenic atrophy (Tybulewicz et al., 1991; Songyang et al., 1995). Since ARG is the 
paralogue of c-Abl and it has some overlapping functions with c-Abl, compound c-
Abl/ARG double homozygous mice have been generated.  They are embryonic lethal with 
defect in neural tube closure, suggesting that these two kinases have essential and 
overlapping functions in neural development in mice (Koleske et al., 1998). In other 
organisms such as Drosophila, the Abelson gene (Abl) shows sequence homology to the 
human c-Abl protein. Introduction of the Abl mutations into fly zygotes results in some 
recessive lethality at the pharate adult pupal stage (Hoffmann, 1991).  
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I. 6.1 c-Abl in bone remodeling 
It has been reported that Abl -/- mice are osteoporotic (Li et al., 2000). The long 
bones of mice deficient in c-Abl contain thinner cortical bones and reduced trabecular 
bone volume (Illustration 2). The bone-resorbing osteoclasts were found to be normal in 
terms of the number and the function compared to their wild type littermates. However, 
study of bone-building osteoblasts revealed defects in their differentiation and 
maturation. Osteoblasts isolated from both the bone marrow and calvarias expressed 
reduced levels of osteoblast markers: alkaline phosphatase (ALP), osteocalcin and 
mineral deposition. The overall effect is a reduction in bone mass, characteristics of an 
osteoporotic phenotype. Further studies of osteoblasts deficient in c-Abl revealed another 
defect in the replication of cells. This is manifested by a flattened cellular morphology 
and reduced capacity for cell division compared to their wild type littermates. This is a 
characteristic of cellular senescence: an irreversible state of arrested proliferation (Tang 
et al., 2001; Pelicci, 2004). This premature senescence of osteoblasts as well as the 
osteoporotic nature of c-Abl knockout mice indicate that this animal is a suitable model 




























Illustration 2: The figure taken from publication (Li et al., 2000) shows that mice 
deficient for c-Abl are osteoporotic by Hematoxylin and Eosin (H&E) staining and 
histological observations (left panel). The Right panel shows a 3-Dimentional uCT high 
resolution representation of the bone defect in senile osteoporosis, with much less bone 
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PART II: p53 
II.1.1 History 
p53 was identified in 1979 as a 53 kilo-Dalton protein (hence the name), 
interacting with the Simian SV40 large T antigen (reviewed in (Hall and Lane, 1997)). 
Later, the importance of p53 in cancer progression is illustrated by the fact that in over 
50% of all human cancers, p53 is mutated, making it a best-studied tumour suppressor 
(Selivanova, 2004).  
II.1.2 Family members 
Two p53 homologs have been uncovered as a p53 super-family of transcription 
factors, p63 and p73 (Levrero et al., 2000). p63 and p73 are functionally and structurally 
related to p53 except that p63 and p73 have an additional conserved domain at their C-
termini (Arrowsmith, 1999). The variable C-terminal extensions contain the sterile alpha 
motif (SAM) domain and an inhibitory domain (ID) whereas p53 has a basic domain. The 
rest of the domain structures including the transactivation domain, the DNA-binding 
domain, and the tetramerization domain are highly homologous among these members. 
This SAM domain of p63 and p73 is a protein-protein interaction module that may have a 
regulatory function. It aids in recruiting protein effectors and may be involved in 
developmental processes (Flores et al., 2002; Arrowsmith, 1999). Functionally, both p63 
and p73 are involved in cell cycle control, apoptosis, DNA repair, senescence and 
differentiation. Similar to p53, they also act as tumour suppressors and function in 
apoptotic pathways downstream of various stimuli, although this is restricted to certain 
isoforms of each member (Irwin et al., 2000). Therefore, p63 and p73 have to be taken 
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into account in order to understand p53's role in cancer, in development and in many 
other areas involving the protein (Blandino and Dobbelstein, 2004). 
II.1.3 Structure and Localization 
Located on the short arm of human chromosome 17 and spanning 20 kilo-bases 
with 11 exons, the p53 gene is subjected to mutations at almost every point of its DNA 
sequence. The structure and DNA sequence of the gene corresponding to key features of 
p53 are well conserved among vertebrate species (Clore et al., 1994). p53 is mutated in 
more than 50% of the primary human tumors and most of the mutations occur at the 
sequence encoding the DNA-binding region of the protein (Soussi, 2000; Lohrum and 
Vousden, 2000; Hernandez-Boussard et al., 1999). p53 is a phospho-oncoprotein and is 
organized into 5 structural and functional regions as shown below (Illustration 3).  











Illustration 3: The diagram above depicts the gene and protein structures of p53 with 5 
functional domains (Adapted from (Cho, 1994; Ko, 1996). The gene p53 has 11 
exons: ;   are the evolutionary conserved regions in the vertebrate genome. The five 
functional domains in the p53 protein include the transactivational domain (TD), the 
short proline rich domain (PR), the DNA-binding core domain (DNA binding domain), 
the oligomerization or tetramerization domain (OD), and C-terminal basic region 
containing the nuclear export and import signals (BR). The right 3-Dimentional structure 
shows that active p53 binds to DNA at the major grooves and the yellow residues are the 
6 most frequent mutated p53 residues indicated in the protein structure. They account for 
more than 90% of cancers caused by p53 mutations at DNA bases or protein amino acids. 
p53 binds to DNA and exerts a variety of cellular functions by activating and repressing a 




Transcriptional active p53 
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II.2 Activation and regulation of p53 
Cellular level of p53 is usually kept low under normal conditions. Wild type p53 
is a labile protein, with a half-life as short as a few minutes and this keeps the protein in 
minute amounts in cells (Agarwal et al., 1998). p53 associates with a 90-kD protein, 
MDM2 (murine double minute) oncoprotein, in the nucleus of cells. It is signaled by 
MDM2 to be transported to the cytoplasm for proteosomal degradation (Momand et al., 
2000; Jablkowski et al., 2005).  Therefore, the occurrence of p53 protein alone in the 
nucleus is generally very transient. However, when the cell is faced with stress conditions 
such as DNA damage, hypoxia, oncogene overexpression, viral infection, heat shock and 
nucleotide depletion, p53 accumulation and activation is induced (Norimura et al., 1996).  
Therefore, p53 activation comes after the stabilization of the protein in the nucleus. A 
variety of positive and negative regulators are identified in the regulation of the specific 
activity of p53. MDM2 serves as the main negative regulator of p53 in cells (Chen, 
2002).  
On the other hand, positive regulatory proteins of p53 such as Alternative 
Reading Frame (ARF) and c-Abl are able to neutralize the inhibitory effects of MDM2 
and thereby result in p53 accumulation and activation (Lin and Zhu, 2003; Sionov, 1999). 
ARF, also a tumour suppressor protein, is able to trigger apoptosis and cell cycle arrest at 
G1 and G2 phases in a p53-dependent manner. Some other positive regulators such as 
BRCA-1 and 14-3-3 б are able to bind to the p53 C-terminus and stabilize the protein 
tetramer structure for transcriptional activity (Brugarolas and jacks, 1997; Yang et al., 
2003).   
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II.3 Target genes and cellular functions of p53 
Post-translational modifications modulate the half-life and the transactivation 
activity of p53, resulting in alteration in expression of its target genes, which control a 
variety of cellular outcomes (Brooks and Gu, 2003). 
II.3.1 p53 functions as a transcriptional activator/repressor 
p53 contains a strong transcriptional activation domain at the N- terminus and 
most of the time it acts as a transcriptional activator. It binds to DNA in a sequence–
specific manner as a tetramer (Carr, 2000). The consensus cognate binding site for p53 
contains two copies or repeats of the 10-mer (5'- RRRCWWGYYY N0-13 
RRRCWRRRCW-3') separated by an in-between 0-13 nucleotides (N), where R is a 
purine base of either G or A; W is A or T; and Y is C or T. Each copy binds a p53 dimer. 
It is reported that when p53 acts as an activator, the repeats are arranged in a head-to-
head (HH) fashion. However when p53 binds to DNA as a repressor, these half-sites are 
arranged in a head-to-tail (HT) way.  It is believed that transactivation of p53 target genes 
is important for p53’s function in apoptosis and cell cycle control (Vogelstein et al., 
2000).  
Many genes involved in the process of apoptosis have been identified to be 
activated by p53. Among them are Bax, Puma and Noxa (Wang et al., 2001). Some genes 
involved in cell cycle control have also been characterized to have p53 binding sites. p21, 
GADD45 and 14-3-3б are amongst the best studied examples (Tomasevic et al., 1999; 
Yang et al., 2003).  
II.3.1.2 Mechanisms of p53 repression:  
In addition to transcriptional activation of genes that contain the p53-binding 
sites, p53 has also been found to transcriptionally repress certain genes.  p53 has been 
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shown to transcriptionally repress the anti-apoptotic gene Bcl-2 by binding to the 
promoter of Bcl-2 (Li et al., 1999). It is also known to repress MAP4, a microtubule 
associated protein involved in cell division (Punga and Akusjarvi, 2003). Survivin, an 
inhibitor of apoptosis, is another protein repressed by p53 (Jin et al., 2005; Hoffman et 
al., 2002). These genes have p53 recognizable elements in their promoters for binding 
and repression. On the other hand, p53 is also capable of inhibiting transcription of genes 
lacking p53-binding sites. This repression appears to be achieved through an interaction 
of p53 with a promoter-bound transcriptional activator (Li et al., 1999; May and May, 
1999). For instance, hTERT and IGF-1 promoters are activated by Sp1, which is inhibited 
by p53 interaction (Kanaya et al., 2000; Ohlsson et al., 1998). Cox-2 promoter is 
activated by an activator NF-Y, which is similarly inhibited by p53 (Subbaramaiah et al., 
1999). p53 can also repress transcription in a DNA binding independent manner through 
the minimal promoter region, suggesting that p53 may interfere with the basal 
transcription machinery (Shaulian et al., 1993; Seto et al., 1992; Thut et al., 1995; Truant 
et al., 1993). In contrast to transcriptional activation, the mechanisms by which p53 
represses gene expression are poorly understood. Moreover, the functional consequences 
of the repression remain largely unexplored. Illustration 4 shows the hypothesized 
mechanisms of p53 repression (Seto et al., 1992; Hoffman et al., 2002; Murphy et al., 
1999).  










Illustration 4: The diagram is extracted from (Ho, 2003). There are three modes of p53 
transcriptional repression. In the first model, p53 interferes with the functions of the 
DNA-binding transcriptional activators A. Activator can on longer associate with the 
basic transcriptional machinery for activation. Therefore, the transcription is off. In this 
model, the binding of the p53 molecule to DNA consensus sequence is necessary. In the 
second model in the middle, p53 interferes with the basal transcriptional machinery and 
the binding of p53 to DNA is not required. In the third model, p53 recruits chromatin-
modifying enzymes such as histone deacetylases to alter the structure of the chromatin. 
As a result, the promoter site is no longer accessible to the transcription machinery and 
therefore, the transcription is off. This particular model is recently under intensive study.  
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II.3.2 p53 in apoptosis 
Programmed cell death, apoptosis, is an evolutionarily conserved cellular process 
for an organism to get rid of cells that are deleterious or unwanted.  p53 can induce 
apoptosis by controlling the expression of proteins involved in apoptotisis (Hickman, 
2002). It can activate the transcription of pro-apoptotic genes or inhibit the expression of 
anti-apoptotic proteins. Generally, there are three mechanisms by which p53 regulates 
apoptosis: 1) p53 has been shown to differentially regulate the expression levels of BAX, 
a pro-apoptotic gene, and BCL-2, an anti-apoptotic gene. p53 transactivates BAX while 
represses BCL-2. These two genes participate in the intrinsic pathway of apoptosis that is 
mediated by the release of cytochrome C from mitochondria. Caspase protein cleavage 
follows, leading to the final event of apoptosis (Manfredi, 2003). Moreover, BAX 
elevation is responsible for close to half of p53-dependent apoptosis induced by 5-FU 
(Fluorouracil) in colorectal cancers. 2) p53 was found to induce genes such as p66shc 
that produces endogenous oxidative stress resulting in cellular output of reactive oxygen 
species (ROS). p66shc encodes a potent inducer of mitochondrial damage and intrinsic 
apoptosis pathways (Shen and White, 2001; Murphy et al., 2004). 3) p53 could also 
mediate apoptosis via mechanisms that are independent of its transcriptional activity 
(Sheikh and Forance, Jr., 2000; Amsterdam et al., 1996).  It was found that p53 with a 
deletion of 30 amino acids from the C-terminus (after its DNA binding domain) fails to 
induce apoptosis, without affecting its ability to induce cell cycle control. Hence, the C-
terminal basic sub-domain is important in controlling the pro-apoptotic activity of p53 
(Yu and Zhang, 2005; Jayaraman and Prives, 1995).  
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II.3.3 p53 in cell cycle arrest 
The ability of p53 to prevent cell growth is paramount to its tumour suppressor 
function.  DNA damage leads to an up-regulation of p53 and an increased transcriptional 
activity of p53. The mechanism by which DNA damage brings about the change in p53 is 
complex and not fully understood. Nevertheless, in response to such stimuli, p53 
suppresses cellular growth through 2 mechanisms: cell-cycle arrest and apoptosis. p53 
can differentiate the extent of DNA damage with unidentified mechanisms. When there is 
mild DNA damage, p53 triggers arrest of the cell cycle until the damage is repaired. If the 
damaged DNA is irreparable, p53 triggers apoptosis.   
The question remains as to how a cell decides when to undergo cell cycle arrest or 
undergo apoptosis and what determine these distinct cell fates.  p53 is able to make the 
decision by activating different target genes depends on the specific cell context and 
levels of DNA damage. p53 induces transcription of CDK inhibitors such as p21 
(Aliouat-Denis, 2005). p21 prevents the cells from exiting the G1-phase when DNA is 
damaged. Induction of genes such as 14-3-3б and GADD45 by p53 could also contribute 
to cell cycle arrest.  It has been reported that high levels of such cell cycle inhibitors 
result in cell cycle arrest instead of apoptosis (Mercer, 1992; Yu et al., 1999). Removal of 
p21 or 14-3-3б leads to apoptosis over cell cycle arrest in cells following DNA damage. 
It is found that expression of pro-apoptotic genes such as Puma and Noxa are induced by 
IR in radio-sensitive tissues such as spleen and gut, indicating occurrence of apoptosis 
(Hudson et al., 2005; Jen and Cheung, 2005). However, there is a strong induction of p21 
in radio-resistant tissues, providing in vivo evidence for selective expression of p53 target 
genes. In addition, p53 also induces cell cycle arrest by binding to E2F, a transcription 
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factor crucial for G1/S transition. This binding prevents E2F from activating genes such 
as c-Myc and c-Fos, which are needed for cells to enter S phase (Hickman, 2002).  
II.4 p53 in cancer and mutations  
More than 50% of human primary cancers have mutations in p53. These 
cancerous cells express mutant p53 forms that are not functional. Amongst the mutations, 
80% are missense mutations, in which one DNA base is exchanged for another 
(Hernandez-Boussard et al., 1999). This results in functionally heterogeneous proteins.  
In addition, there exists inheritable p53 mutations. Pedigree studies reveal a high 
incidence of cancer in some families. One case is Li-Fraumeni syndrome (LFS) which is 
caused by germline mutation of p53, a rare inherited syndrome of cancer predisposition. 
It was reported that individuals who inherit LFS are subjected to a number of different 
cancers from a young age (Varley, 2003; Vahteristo et al., 2001). Of course, malignant 
transformation of normal cells is a much more complicated process that requires not only 
dysfunctional p53. Other requirements include the presence of telomerase to maintain 
telomere length and/or expression of activated oncogenes (Kastan ad Bartek, 2004; Sherr 
and McCormick, 2002).  
II.5 Possible roles for p53 in aging and mouse development  
II.5.1 Senescence   
Cellular senescence is a state of irreversible cell cycle arrest. Senescent cells have 
the morphology of increased nucleoli, increased cytoplasmic microfilaments and 
increased number of multinucleated cells. The cells appear enlarged, flattened and also 
express senescence-associated β-galactosidase. Unlike the quiescent state, senescent cells 
are metabolically active but cannot reenter the cell cycle. Cell senescence has been 
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proposed to act as a mechanism to suppress tumorigenesis (Campisi, 1997; Chernyavsky 
et al., 2005). In humans, senescence is marked by progressive shortening of telomeres, 
which are specialized structures that aid in protecting the chromosome ends (Campisi, 
1997). Telomeres get shorter with each cell division in culture or in self-renewing tissues 
(Pandita, 2002). As a result, permanent cell cycle arrest, characteristic of replicative 
senescence, occurs due to activated cell cycle checkpoints triggered by critically 
shortened telomeres (Takai et al., 2003). The type of cell cycle arrest is similar to those 
activated upon double strand breaks. Moreover, DNA damage, oncogenes, mitogenic 
signals can also induce senescence via the activation of regulatory proteins like p53, Rb  
and cell cycle inhibitory proteins p16 and p21. In cells with shortened telomeres, 
chromosomal end-to-end fusions may occur and this can fuel cancer initiation (Serrano et 
al., 1997; Karlseder et al., 2002).  
p53 is essential for the cell senescence response as it promotes transcription of 
genes like p21 that induces cell cycle arrest and senescence. p53 responds not only to 
shortened telomeres and DNA damage but also to overexpression of certain oncogenes 
(Ben Porath and Weinberg, 2004). Inactivation of the p53 pathway allows the bypass of 
senescence and facilitates the onset of cancers. Study of the Werner syndrome, a 
premature aging disorder caused by mutations in the WRN gene, also suggested that p53 
plays an important role in the orchestration of replicative senescence (Huang et al., 
1998). WRN was found to physically interact with p53 and both protein levels are 
affected by DNA damage. However, the mechanism of how p53 senses senescence-
inducing stimuli remains elusive. Nevertheless, p53 and p21 protein levels are found to 
be up-regulated during senescence while that of p16 is up-regulated after entering the 
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senescent state. Therefore, cellular senescence is regulated by two parallel pathways. One 
is through the regulation of p21 by p53, and the other is via p16, leading to 
hypophosphorylation of pRb (Alcorta et al., 1996). The overall result is an inactive E2F 
complex and a permanent and irreversible arrest at G1 phase (Zhang et al., 2003; 
Marcotte and Wang, 2002). Cell senescence is intensively studied not only because of its 
connection with aging, but because of its implication in cancer therapy. How to induce 
tumour cells to undergo senescence or enter senescence before tumorigenesis remains a 
question to be solved. Furthermore, recent studies have linked senescence with 
development as both require cells to exit from the cell cycle and undergo terminal 
differentiation (Smith and Pereira-Smith, 1996; Shay et al., 1991; Hara et al., 1996; 
Huang et al., 1998).  
II.5.2 Development       
p53 is dispensable for normal mouse development as initial studies show that all 
mice homozygous null for p53 are viable even though they are highly susceptible to 
tumors by 6 months of age (Donehower et al., 1992). Despite the viability of most p53 
null mice, accumulated evidence has also shown that p53 may regulate differentiation 
and the response of embryonic cells to diverse environmental stresses. Later in 1995, a 
small portion of the mice embryos deficient in p53 were demonstrated to show abnormal 
neural tube closure. This is a condition termed exencephaly, characterized by defects that 
form an overgrowth in the neural tissue region of the mid-brain. Exencephaly is one of 
the common causes of infant mortality in humans (Sah et al., 1995). In the same year, 
another developmental abnormality was identified in homozygous p53 embryos, 
predominantly in the female embryos (Armstrong et al., 1995). A significant portion of 
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the female embryos also display craniofacial malformations. These include ocular 
abnormalities and defects in the upper incisor tooth formation. Reduced female offspring 
was also observed from heterozygous mice matings. This implies a physiological role of 
p53 at early embryonic development and further investigation is necessary (Billon et al., 
2004; Choi and Donehower, 1999; Migliorini et al., 2002). In other animals such as 
Xenopus, p53 activity is essential for normal development (Takebayashi-Suzuki et al., 
2003). It was suggested that under-expression of p53 can lead to increased risk of 
malformations or even embryonic lethality. 
p53 may be an important embryo-protective gene as embryos homozygous null 
for p53 alleles are more susceptibility to teratogenicity from DNA damage stress. 
Heterozygous and homozygous p53-deficient embryos exhibited increased ontogenicity 
towards benzo[a]pyrene, an environmental teratogen (Norimura et al., 1996). Later, the 
transcriptional activity of p53 was studied following irradiation in mouse development. 
From the transgenic mice that contain a p53 response element fused to a lacZ reporter 
gene, p53 was found to be present at a high level in the majority of cells in early embryos 
in response to irradiation. However, the heterogeneity of the p53 response becomes 
apparent in individual cells and tissues later in development. p53 accumulation was 
observed in splenocytes, thymocytes and osteocytes, but not in the hepatocytes of 
irradiated adult mice (MacCallum et al., 1996). This suggests that the induction of p53 
from upstream signals is controlled in a tissue or even cell specific manner at different 
stages of embryonic development. Downstream events resulting from p53 induction as a 
response to irradiation are also tightly regulated in a similar manner. Massive apoptosis 
occurs in the thymus and mice spleen, but not in the osteocytes, suggesting that p53 may 
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initiate distinct responses in different tissues. Furthermore, in an assessment for liver 
development in p53 knockout mice, it was found that p53 deficiency caused no cell-
cycle-induced perturbation of embryonic and perinatal liver development. However, there 
exist obvious signs of disturbance in the differentiation of p53-/- adult liver cells, as 
manifested by appearance of small hepatic blast-like cells. Overall, these studies suggest 
that the p53 protein may have multiple activities in regulation of developmental processes 
(Komarova et al., 1997). Similarly, transgenic mice were used in which a lacZ transgene 
is driven by a p53-dependent promoter of the MDM2 gene. The promoter activity was 
then monitored in response to irradiation in mouse embryos of different p53 genotypes. 
There is much less induction of the lacZ in mice carrying only one copy of the wild type 
p53 (haploinsufficiency) and maximal p53 activation occurred in relatively less 
differentiated but rapidly proliferating cells (Gottlieb et al., 1997; Prives, 1998).  
Therefore, the tight control of p53 expression in embryonic cells is demonstrated to be 
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PART III: Interaction of c-Abl with p53 
p53 acts as the cellular guardian of the genome. As mentioned, the level of p53 
protein is subjected to tight regulation at multiple levels in order to maintain the DNA 
integrity (Sionov et al., 1999). c-Abl, the stress-activated non-receptor tyrosine kinase 
has been reported to be critical for the maximal and efficient accumulation of active p53 
following DNA damage under physiological conditions (Goldberg et al., 2002). Under 
normal conditions, c-Abl is necessary for the proliferation of cells deficient in p53 
(Whang et al., 2000). On the other hand, under genotoxic stress such as exposure to γ-
irradiation, c-Abl inhibits the nucleo-cytoplasmic shuttle of p53 and thus antagonizes the 
inhibitory effects of MDM2 on p53. c-Abl binds and tyrosine phosphorylates MDM2 on 
tyrosine residue 394 in vivo and in vitro and thereby disrupts the complex of MDM2 and 
p53. Consequently, the ubiquitination and nuclear export of p53 for proteosomal 
degradation is prevented and p53 accumulation occurs inside the cells.  
c-Abl physically interacts with p53 via the DNA binding domain of c-Abl and this 
interaction occurs after activation of c-Abl in an ATM-dependent manner upon DNA 
damage. The interaction between c-Abl and p53 also requires the C-terminus of p53 and 
p53 tetramerization. This binding with c-Abl stabilizes the specific interaction of p53 
with DNA and enhances the transcriptional activity of p53 (Levav-Cohen et al., 2005; 
Nie et al., 2000; Sionov et al., 1999). However, c-Abl does not tyrosine phosphorylate 
p53.  
Similar to cellular functions of p53, c-Abl also participates in cell cycle 
checkpoint control and programmed cell death. When overexpressed, c-Abl-mediated 
apoptosis was found to be mainly p53-independent, as c-Abl induced apoptosis happened 
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in both wild type and p53 deficient cells (Kharbanda et al., 1995; Wen et al., 1996). 
However, c-Abl-mediated G1 cell cycle arrest requires functional p53. A search for c-
Abl-mediated p53 independent apoptotic pathway has led to the recovery of p73. p73 was 
found to be tyrosine phosphorylated on residue tyrosine 99 and activated by c-Abl. It 
serves as a mediator and essential component of c-Abl induced apoptosis (Yuan et al., 
1999; Gong et al., 1999). Mice deficient for c-Abl exhibit retarded growth and mice 
deficient for both p53 and c-Abl are nonviable (Tybulewicz et al., 1991; Whang et al., 
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PART IV: Bone Development 
IV.1 Skeletal system 
IV.1.1 Bone Structure 
The vertebrate body is supported by an endoskeleton made of cartilage and bone. 
Our bone is a dynamic organ that performs several functions. First, it gives the body 
mechanical support and protection. Skeletal parts such as skull and ribs protect internal 
organs and soft tissues from mechanical damage and aid in the protection of the central 
nervous system. Secondly, bone serves as a site for housing and support of hematopoiesis 
(Manolagas and Jilka, 1995). Bones contain a central cavity inside the compact cortical 
bones and between the spongy trabecular bones. This cavity is filled with bone marrow, 
which contains stem cells for all blood cells. Thirdly, bone is also a major mineral store 
containing huge reservoirs of 99% of body calcium and 88 % of body phosphate (Rodan 
and Harada, 1997). It serves as an internal "fail safe" mechanism for the maintenance of a 
constant ionic environment in the extracellular fluid (Weiner and Traub, 1986).  
Two types of bone comprise the skeleton. Cortical bones are compact and 
cancellous trabecular bones are spongy in nature. Unlike the cortical bone, trabecular 
bones are less dense and provide only a small portion of the skeletal strength. Both 
cortical and trabecular bone contain bone marrow (Karsenty, 1999; Cohen, Jr., 2000). 
IV.1.2 Bone remodeling  
Bone remodeling requires balanced, coordinated activities of two main types of 
cells: osteoblasts and osteoclasts, that maintain a steadily controlled bone mass and bone 
density (Chien and Karsenty, 2005; Mosekilde, 1990). Approximately 10% of our bone 
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mass is replaced each year with newly formed bones and the bone calcium content turns 
over with a half-life of 1-5 years (Karsenty, 2001; Reddi, 1997). Bone formation is faster 
than bone resorption in childhood and teenage years, and to a smaller extent under 
mechanical loads. As a result the size of bones increases during growth. Bone resorption 
then becomes faster than bone formation after that. This shift is controlled by steroid 
hormones as well as growth hormones.  In general, bone formation is a slower process 
than bone resorption. It takes at least 3 months to rebuild the bones resorbed in 3 weeks 
(Karsenty and Wagner, 2002; Karsenty, 1999). Numerous hormonal and growth factors 
are found to exert influences on differentiation and recruitment of osteoblasts and 
osteoclasts. They therefore perform endocrine effects on overall skeletal tissues (Takeda 
et al., 2001; Kundu et al., 2002). Only BMPs will be discussed here. 
Bone Morphogenic Protein (BMP):   
BMP was identified as early as 1889. It was successfully purified in 1992 from 
demineralized bone matrix (reviewed in (Yagi et al., 2003)). BMP belongs to a super-
family of growth factors, the TGF-β family (Balemans et al., 2002). There are more than 
10 proteins in the BMP family and amongst them, BMP2 and BMP4 have 80% sequence 
homology and are often used in laboratories to stimulate osteoblast differentiation. BMPs 
can also promote the multipotent mesenchymal stem cells to differentiate into mature 
osteoblasts. It induces ectopic bone formation in vivo via a pathway reminiscent of 
endochondral bone formation. These “bone stimulators or bone generators” are able to 
move around and bind to receptors on the cell surface and activate BMP signaling 
cascades involving the cytoplasmic Smad molecules. Smads then activate bone specific 
transcription factors or other related genes involved in osteogenesis. The BMP receptors 
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are made up of Type I and Type II, both of which are Serine/Threonine Kinases and are 
intensively studied due to their involvement in cellular proliferation and differentiation 
(Bain et al., 2003; Bitgood and McMahon, 1995).  
IV.2 Bone cells       
Osteoblasts:  
Osteoblasts are bone forming cells that synthesize collagen and generate bone 
matrix. They express large amounts of alkaline phosphatase and contain lots of rough 
endoplasmic reticulum, likely to facilitate secretion of collagen rich ground substances 
essential for hydroxyapatite mineralization (crystals of calcium compounds). Osteoblasts 
vary in shape and size. They are closely arranged in several layers and appear cuboidal 
during rapid osteogenesis. Osteoblasts are mononuclear cells of mesenchymal origin, 
they proliferate and differentiate continuously regardless of age and can be controlled by 
many factors as they contain receptors for estrogen, BMPs, PTH and vitamin D (Odorico 
et al., 2001; Pash et al., 1995).  
Osteoclasts:  
Osteoclasts are derived from hematopoietic stem cells (HSCs) in the bone 
marrow. They come from the same mononuclear progenitors that also produce monocytes 
and macrophages (Suda et al., 1999; Udagawa et al., 1990). They are very large, 
multinucleated bone-resorbing cells (MNCs) of up to 100 µm. They exist in varying 
shapes from flat to round, depending on the resorption activity of the cells. They also 
contain numerous pleomorphic mitochondria and a variety of vesicular structures. 
Osteoclasts are also characterized by a ruffled edge where active resorption takes place. 
They are the main protagonists involved in breaking down or resorption of bone matrix 
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(Hentunen et al., 1995). Like osteoblasts, osteoclasts are also be controlled by various 
hormones and growth factors. Osteoclasts express receptors for estrogen and calcitonin, 
both exert inhibitory effects on osteoclastic bone resorption (Shevde et al., 2000). These 
cells also help in the maintenance of mineral homeostasis of extracellular fluid. 
Dysfunction of osteoclasts causes diseases like osteopetrosis and Paget's disease due to 
defective bone resorption (Yasuda et al., 1998; Calle et al., 2004).  
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IV.3 The bone precursor cells 
Mesenchymal stromal cells (MSCs) are housed in the bone marrow and are 
pluripotent (Pittenger et al., 1999). They can be directed to differentiate into a 
heterogeneous population of non-hematopoietic tissues. The bone marrow also houses 
HSCs, which are the progenitors for osteoclasts in addition to blood cells. MSCs interact 
with HSCs and provide a structural framework and a regulatory microenvironment to 






Illustration 5: The picture extracted from (Harada and Rodan, 2003) shows 
mesenchymal stem cell lineages. Mesenchymal progenitors have the potential to become 
differentiated into many cell types like adipocytes, chondrocytes, myocytes and 
osteoblasts. The terminal differentiation of a specific cell type is under the control of 
many transcription factors.  
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MSCs are adherent and the number of MSCs can be quantified by colony-forming 
unit (CFU) assays. It has been shown that when injected into animals, adult MSCs are 
capable of homing to a site of injury and restoring tissue function. This suggests that 
MSCs contain stromal precursors capable of self-renewal and differentiation into muscle, 
fat, cartilage and bone cells (Frankel, 2000). Bone marrow cells can provide micro-
environmental function to influence proliferation and differentiation of hematopoietic 
precursor cells (Harada and Rodan, 2003). However, MSCs show reduced proliferative 
potential with increasing age. Meanwhile, several diseases or bone disorders have been 
associated with the abnormal function of these stromal precursor cells. This has further 
implications for stromal cells in tissue engineering and in studies of stem cell plasticity 
(Rodan, 1997; Rodan and Harada, 1997; Jiang et al., 2002).  
IV.4 Osteoblastogenesis 
Transcription factors play vital roles in determining the development of 
osteoblasts. Among them, Runx2 (Runt-related transcription factor 2), and osterix will be 
discussed here. Other transcription factors important in osteogenesis include Sox9 (sex 
determining region Y-box 9), Dlx5 (Distal-less homeobox 5), and some HLH (Helix-
loop-Helix type) family members (Robledo et al., 2002; Akiyama et al., 2002). AP1 
complex family members including c-Fos and c- Jun and ATF families of proteins are 
also known to play important roles in bone remodeling and skeletal development 
(Grigoriadis et al., 1995; Akatsu et al., 1989).  
Runx2:  
Runx2 is a runt family member, contains different isoforms. It is also known as 
PEBP2A1/Osf2/AML3/ Cbfa1 (core-binding factor). Runx2 is the earliest determinant of 
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osteoblast differentiation and its expression defines a bipotential cell type coined an 
osteochondroprogenitor (Ducy et al., 1997). It is indispensable and a prerequisite for 
osteoblastic differentiation. The knockout mice completely lack osteoblasts and show a 
decrease in the number of chondrocytes and a defect in osteoclast differentiation (Komori 
et al., 1997). Runx2 expression level is high in normal osteoblasts and moderate in other 
cells like chondrocytes and T cells, indicating that it might exert variable effects in a cell-
type specific manner. When over-expressed in C3H10T1/2 cells, a mouse non-skeletal 
cell line, Runx2 induces the expression of osteoblastic markers like alkaline phosphatase 
and osteocalcin, suggesting that elevation in Runx2 is sufficient to induce osteoblast 
differentiation (Kundu et al., 2002; Ueta et al., 2001).  
Osterix:    
Osterix was identified as a zinc-finger containing transcription factor, essential for 
skeletogenesis (Kim et al., 2005). It was initially identified in 2002 as a transcription 
factor whose expression is enhanced upon BMP stimulation (Nakashima et al., 2002). 
Osterix is specifically expressed in all developing bones and there is no bone calcification 
observed in mice deficient for osterix. This suggests a specific effect for osterix in 
osteoblast differentiation. Furthermore, mesenchymal cells from osterix null mice do not 
deposit bone matrix. The osterix function was placed downstream of Runx2 as cells 
deficient in osterix still express Runx2, but cells deficient for Runx2 do not have osterix 
expression (Lee et al., 2003). Similar to Runx2, overexpression of osterix in C3H10T1/2 
cells induces the expression of osteoblastic markers as well (Huang et al., 2004).  
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Markers of Osteoblastogenesis: 
Various biochemical markers can be used in vitro to assess the progress and rate 
of osteoblast differentiation and mineralization. Alkaline phosphatase (ALP) is used as an 
early marker of osteoblast differentiation although it is not very specific for osteoblasts 
(Zhou et al., 1994). A highly specific marker is osteocalcin that is highly expressed and 
secreted by mature osteoblasts. Osteocalcin is a bone matrix protein, whose expression 
can be assessed by reverse transcriptase-polymerase chain reaction (RT-PCR) or 
Northern blotting. Mineral deposition by osteoblasts, a marker to assess bone formation, 
can be assayed by Von Kossa staining (Wang et al., 1999).  
IV.5 Osteoclastogenesis 
Formation of osteoclasts requires stimulation at two critical steps. The first step is 
the lineage-step differentiation of HSCs to osteoclast progenitor, a common precursor cell 
for monocytes, macrophages and osteoclasts (Takahashi et al., 1988). The second step is 
the differentiation of mature active osteoclasts from osteoclast progenitors. 
Multinucleated osteoclasts form from fusion of precursor cells (Udagawa et al., 1990). 
Many factors including cytokines, ions, hormones and even extracellular matrix elements 
like osteopontin and osteocalcin play a role in osteoclastogenesis. Three factors are most 
important and well-studied in the process of osteoclastogenesis. They are M-CSF, 
RANKL and OPG (Osteoprotegerin) (Udagawa et al., 1990; Shevde et al., 2000).  
M-CSF: 
M-CSF (also known as CSF-1) is a macrophage lineage-specific mononuclear 
phagocyte colony-stimulating factor (Bourette and Rohrschneider, 2000). It is 
synthesized by mesenchymal cells. M-CSF is a cytokine and also a growth factor. It is 
important for the recruitment, differentiation, migration, activation and survival of 
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osteoclasts as well as other hematopoietic cells of the monocyte-macrophage lineages. In 
addition, M-CSF is also expressed in other types of cells, like ovarian and epithelial cells 
(Gilbert et al., 1989). It can be in the soluble or membrane associated forms, and binds to 
a receptor with highly specific affinity. The receptor is encoded by the proto-oncogene c-
Fms and is present in both osteoclast progenitor and mature osteoclasts. In the animal 
model op/op mouse that is deficient for M-CSF, there are not only low numbers of 
macrophages and monocytes, but also an almost absence of osteoclasts (Fleisch et al., 
1993; Sundquist et al., 1995). As a result, the mice develop osteopetrosis. Reconstitution 
of M-CSF increases the number of osteoclasts. The mechanism of how M-CSF regulates 
osteoclasts and other cells, as well as different functions of various forms and locations of 
this molecule warrant further investigation.  
RANKL and OPG:  
Osteoclast precursors circulate in the peripheral blood. They have on their cellular 
surface RANK and c-Fms receptors. These receptors bind to RANKL and M-CSF 
respectively. RANKL promotes osteoclast formation, activation and survival upon 
engagement with the receptor (Li et al., 2000). OPG is the decoy receptor and inhibitor of 
RANKL. It functions as a paracrine inhibitor of osteoclasts, curbing both their production 
and activity (Maimoun et al., 2005; Siggelkow et al., 2003).  
Markers for Osteoclastogenesis:  
Tartrate resistant acid phosphatase (TRAP) is secreted in substantial amount by 
osteoclasts. It is the most commonly used biochemical marker for osteoclast 
differentiation (Lindunger et al., 1990). Osteoclasts could also be characterized by its 
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multi-nucleation feature. Formation of resorption pits is used to assess the bone 
resorption function of these cells (Flynn et al., 1999). 
IV.6 Coupling between Osteoblasts and Osteoclasts 
It was reported that active osteoclast maturation requires the presence of coupling 
factors from other bone-marrow derived cells. These cells such as osteoblasts, monocytes 
and lymphocytes are mandatory for absorptive activity of osteoclasts (Harada and Rodan, 
2003; Takahashi et al., 1988). However, the exact nature of the primary osteoclastic stem 
cells is still unknown. In certain situations, osteoblasts initiate bone resorption. Reports 
indicate that there might be signal stimuli from osteoblasts that stimulate osteoclastic 
precursor cells to become osteoclasts. For example, OPG is a cytokine that is secreted by 
osteoblasts and their precursors. RANKL and M-CSF could also be synthesized by 
osteoblastic precursors and stimulate osteoclastogenesis (Bourette and Rohrschneider, 
2000). Therefore, osteoblasts could promote osteoclastogenesis. On the other hand, 
insulin-like growth factors (IGFs) and TGF-βs are growth factors released during 
resorption and are known to be stimulators of bone formation (Boyle et al., 2003). 
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IV.7 Bone diseases and therapy 
Osteoporosis 
Osteoporosis is the most common form of bone diseases. It is characterized by the 
loss of bone mass, reduced bone mineral density (BMD) and micro-architectural 
deterioration of the bone tissue (Ralston, 2002). This condition leads to weak, brittle and 
porous bones. 8 million Americans already have the disease. It is not a disease affecting 
only women, one out of 5 men is also affected by the disease due to deficiency of 
testosterone, the male hormone (Gennari et al., 2003; Seeman et al., 1989). There are 3 
types of osteoporosis. Type 1 is also known as post-menopausal osteoporosis. It is 
characterized by a progressive and excessive loss of trabecular bone mass due to a lack of 
estrogen when ovarian function fails. Type II is also known as age-associated 
osteoporosis or senile osteoporosis. It is caused by the natural ageing process. Some 
studies also point to malabsorption of mineral and vitamins as a cause. Both cortical 
bones and trabecular bones are affected in both genders in this type (Boonen and 
Dequeker, 1996). Secondary osteoporosis is the third type that could be caused by certain 
medications such as glucocorticoids, some sleeping pills, loop diuretics. Other causes 
include a variety of endocrine and metabolic effects such as hyperthyroidism, pregnancy 
and even depression (Melton, III et al., 2002). 
Osteosclerosis: 
Osteosclerosis is an abnormal hardening of the bone. It is associated with a 
moderate increase in BMD. Osteosclerosis may occur with eburnation, a degeneration of 
the bone during osteoarthritis. It could also accompany disorders such as 
hyperparathyroidism, Paget’s disease and leukemias (Villareal et al., 1992). In addition to 
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BMD, signs of osteosclerosis also include thickened bony articular surfaces, dense 
epiphyses and metaphyses, and increased rates of bone accretion. Increased BMD in 
osteosclerosis is associated with dense and thickened cortical bones, probably due to 
replacement of cancellous trabecular bones by compact cortical bones. There is also 
enhanced osteoblast function as manifested by elevated serum alkaline phosphatase 
activity. Osteosclerosis could also occur because of mutations in genes such as TGF-β 
and LRP5 gain-of-function mutations that increase osteoblast activity (Beyer et al., 
1990). However, little is known about the precise pathogenesis of this bone disease and 
why increased osteoblast differentiation only accompanies moderate increase in bone 
mass. Bone fractures are rare in osteosclerosis because of the normal bone quality 
(Jochum et al., 2000). Studies of the mechanisms of osteosclerosis may help us to 
understand bone development and other bone associated disorders. 
Bone tumour/cancer: 
Like all other cancers, there are benign and malignant forms of bone tumour. 
Although not life-threatening, benign tumors cause bone fractures and disabilities by 
compressing on healthy bone tissues. They even replace healthy bone cells with abnormal 
ones. Malignant forms of bone tumors are often life-threatening as they are able to 
metastasize (O'Connell et al., 1998). Osteosarcoma is the most common form of bone 
cancer. It is a primary bone cancer as it develops in growing bones, normally from 
osteoblasts. On the other hand, secondary cancers spread to bones from other organs. 
Bone cancer may be very painful and sometimes the affected bone marrow is 
accompanied by a weaker immune system as well (Toguchida et al., 1992). 
                                                                       Chapter 1-Introduction Part V; DNA damage 
 44
PART V: DNA damage 
V.1 Types of DNA damage 
V.1.1 Causes of DNA damages 
DNA is the blueprint for operation of each cell. Damaging it means disturbance of 
the repository of hereditary information that determines our very phenotypic appearance 
(Rich et al., 2000). Detrimental outcomes such as cancer and aging may also result. 
Therefore, it is important to avoid DNA damage and to maintain the genomic integrity. 
DNA damage constantly occurs due to external and internal stress (Shiloh, 2001b). It can 
be classified into many types and one way is to look at the source of the damage, i.e. 
exogenous and endogenous. Some well-known and intensively studied exogenous agents 
include ionizing radiation (IR) and Ultraviolet (UV) light exposure. In addition to 
external factors, genomic DNA is also under the stress from endogenous factors (Kastan 
and Bartek, 2004). These include spontaneous damages due to deamination, depurination 
of bases and cellular metabolism. Reactive oxygen species (ROS) produced during ATP 
generation in mitochondria can modify bases of DNA as well as cause oxidative damage 
to cellular proteins and lipids (Li et al., 1999).        
V.1.2 Types of DNA lesions 
Many types of DNA damage are generated depending upon the genotoxic stress 
encountered by the cell (Takahashi and Ohnishi, 2005). There are three major types of 
DNA lesions: double stranded DNA breaks (DSBs), single-stranded DNA breaks (SSBs) 
and base modifications (van Veelen et al., 2005). Base modifications occur at a high 
frequency and include three main types. First, deamination of bases occurs when there is 
a conversion from an amino to a keto group. For example a cytosine is deaminated to 
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form a uracil. This results in a change in the nature of complementary base pairing. 
Secondly, chemical modification of bases could occur when a methyl or alkyl group is 
added to the base (Smith and Sowden, 1996). Other base modifications include oxidation, 
hydrolysis and mismatch of bases. ROS is one potent inducer of some base 
modifications. Thirdly, photo-damage of bases occurs under UV (Fritz and Smerdon, 
1995). Another common type of DNA lesion is base loss. It occurs when there is a loss of 
a purine (Adenine, Thymine) or a pyrimidine (Guanine, Cytosine). The unstable glycosyl 
bond linking DNA bases with deoxyribose sugar backbone creates this 
apurinic/apyrimidinic (AP) site, also known as an abasic site (Evans et al., 2000; Boiteux 
and Guillet, 2004).  
DSBs and SSBs 
Sometimes one strand of the DNA helix is broken when cells are exposed to a 
DNA damaging agent, this kind of lesion is called a SSB (Caldecott, 2003a). When both 
complementary strands of the DNA double helix are broken, a DSB results. DSBs and 
SSBs are generated at a low frequency under normal cellular conditions. They are caused 
by enzymes like topoisomerases and nucleases. Topoisomerase breaks and rejoins DNA, 
while nucleases digest DNA and RNA. DSBs can also be generated when replication 
forks stall at sites of DNA damage, and during gene shuffling processes in lymphocyte 
maturation. However, the frequency of DSBs and SSBs is increased dramatically under 
external stress conditions like IR (Caldecott, 2003b; Petrini, 1999; Datta et al., 2005).  
When DNA damage is incurred by the cell, it initiates three major responses. These are 
cell cycle arrest, programmed cell death and DNA repair (Shiloh, 2001b). 
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V.2 Cellular responses  
Cells respond to DNA damage in different ways, depending on the types and the 
severity of DNA lesions. When cells sense that the extent of the damage is not too severe, 
cell-cycle checkpoints are activated and cells will stop dividing (Kastan and Bartek, 
2004; Enoch and Norbury, 1995a). During the pause, DNA repair enzymes start to fix the 
damages and the cells will be rescued (Niida and Nakanishi, 2005). On the other hand, 
when cells sense the severity of the damage is beyond repair, it may activate apoptotic 
signaling cascades (Bates and Vousden, 1996). 
V.2.1 DNA Repair 
Various repair mechanisms have evolved by the cell to recognize those DNA 
errors and fix them. Even in prokaryote bacteria, a substantial number of genes are found 
to be devoted solely to DNA damage repair, suggesting the importance of the process. 
There are two major kinds of repair mechanisms for DSBs; the choice depends largely on 
the stage of cell cycle progression at the point of assault. They are Non-homologous end 
joining (NHEJ) and homologous recombination repair (HRR) (Dudas and Chovanec, 
2004). Both processes of NHEJ and HRR are highly conserved in eukaryotes. They 
require the stepwise and coordinated actions of multi-protein complexes, although the 
two processes differ distinctly from one another and function in complementary ways to 
effect DSB repair (Hefferin and Tomkinson, 2005).  
NHEJ: Non-homologous end joining is the predominant DSB repair mechanism 
in mammalian cells. It repairs DSBs directly, without any information needed from a 
homologous template. The process is rapid and mediated by the concerted action of a 
series of proteins, starting with the Ku70/Ku80 heterodimeric proteins (van Attikum and 
Gasser, 2005). Ku70/Ku80 are abundant proteins with ATPase and possible helicase 
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activities. It is believed that the Ku70-Ku80 dimer first detects the exposed ends of the 
fragmented DNA strands and then binds to the ends of the DSB in a non-sequence 
dependent manner. Recruitment of the catalytic subunit of the DNA-dependent protein 
kinase (DNA-PKcs) follows (Hefferin and Tomkinson, 2005). DNA-PKcs forms a 
holozyme or trimeric protein with the Ku proteins (Ku-DNA-PK) and start the process of 
synapsis. In the process, the two broken ends are held in close proximity for 
juxtaposition. Single stranded DNA (ssDNA) could be generated during the process and 
NHEJ was known to be inefficient in yeast unless the two DNA strands bear mutually 
cohesive overhanging ends (Lees-Miller and Meek, 2003; Jackson, 1999). Other proteins 
such as polymerase and nuclease then join, preparing the ends for rejoining. DNA repair 
is completed after ligation by DNA ligase IV with the assistance and cooperation of X-
ray cross-complementing (XRCC4) factor in a complex (Featherstone and Jackson, 
1999). However, NHEJ is less accurate and the correction is error-prone. There may be 
addition or removal of a few nucleotides at the repair site due to the trimming of the ends 
before juxtaposition. Sometimes, there are small deletions of the DNA sequence after 
ligation, which also leads to inaccurately repaired DNA (Hopfner et al., 2002; Khanna 
and Jackson, 2001). In serious cases, there is translocation of a gene due to occurrence of 
two breaks, diseases such as Burkett’s lymphoma and CML may even result. The former 
is due to the translocation of the inactive c-Myc gene to an active area, while the latter is 
due to translocation of two arms of different chromosomes. Both result in uncontrolled 
cellular growth (Difilippantonio et al., 2002; Zhu et al., 2002).  
HRR: DSBs in HRR is repaired using the duplicate set of DNA as a template to 
retrieve the genetic information. This process often occurs at late S and G2 phases of the 
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cell cycle, when there is a good copy of the undamaged sister chromatids available 
(Thompson and Schild, 2001). The repair process can be very precise and is of high 
fidelity based on homologous recombination (Dudas and Chovanec, 2004).  
HRR pathway is initiated and mediated by the Mre11-Rad50-Nbs1 (MRN) 
complex and Rad51-associated proteins (Aguilera, 2001). The process starts from the 
production of 3’ ssDNA overhangs. These overhangs could be a result of the nucleolytic 
resection of the DNA DSB in the 5' to 3' direction or directly from the DNA assault. 
After the recognition of the damage, strand invasion first occurs. Rad51, a homologue of 
the bacterial RecA protein, binds to the newly generated ensuing ssDNA exposed ends 
and forms a nucleoprotein filament.  
Other proteins are also involved in this process, for example, breast cancer 
susceptibility protein (BRCA1), BRCA2, RAD52, RAD54 and replication protein A 
(RPA). They serve as auxiliary proteins in the nucleofilament formation and some of 
them may even help to activate the RAD51 protein in strand invasion (Liu and West, 
2002; Daboussi et al., 2002; Huber et al., 2001). Uncoiling of the DNA double helix is 
necessary for other enzymes to come in, and this may be assisted by RPA and RAD51. 
RPA only recognizes single stranded DNA. Rad52 was reported to compete with the 
binding of Ku to DSBs and the outcome of the competition may result in which pathway 
of the DSBs repair is engaged by the cell. Nevertheless, HRR continues when the RAD51 
nucleoprotein filament interacts with an undamaged DNA and searches on the sister 
chromatid for a homologous region (Shin et al., 2004; Baumann and West, 1998). Strand 
displacement then occurs when RAD51 catalyzes the exchange of the damaged DNA 
with the good copy. This process is referred to as the DNA strand exchange, displacing 
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some DNA known as the D-loop. In the last bit, a DNA polymerase copies the genetic 
information from the undamaged stand and extends the 3' end of the invading strand by 
recreating the proper nucleotide sequences. Subsequent ligation by DNA Ligase I and 
cleavage of the Holliday junction or DNA crossovers at the repair site “glues” the new 
DNA together. This yields two precise, error-free, accurately corrected DNA molecules 
(Wyman et al., 2004). Finally, the last troop of enzymes is required to proofread the 
corrections along the DNA strands to ensure the genomic integrity. Impaired HRR 
mechanism leads to an inability of the cells to successfully traverse S-phase of the cell 
cycle (Bernstein et al., 2002; Valerie and Povirk, 2003).  
V.3 ATM/ATR signaling 
DNA damage activates signaling cascades, which assist in making the decision to 
effect a particular cellular response. At the center of these damage triggered signaling 
networks are phosphoinositide-3-kinase-like kinases (PIKKs) that include members like 
DNA-PKcs, Ataxia Telangiectasia Mutated (ATM) and Ataxia Telangiectasia and Rad3-
related (ATR) (Shiloh, 2001b).  
V.3.1 PIKK family  
Phosphoinositide-3-kinase (PI-3K) family members are lipid kinases. Their 
metabolites like PI(3,4,5)P3 are amongst the most versatile intracellular signaling 
molecules (Djordjevic and Driscoll, 2002). They mediate the actions of the majority of 
growth factors and cytokines. On the other hand, the PIKKs is a family of atypical 
kinases. Despite their homology to lipid kinases of the PI-3K family, PIKK family of 
proteins seems to be exclusively protein kinases, predominantly serine/threonine 
(Ser/Thr) kinases. There are 6 members in the family: ATM, ATR, DNA-PKcs, ATX, 
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mammalian Target Of Rapamycin (mTOR), and TRRAP. These members are involved in 
a variety of cellular events such as DNA damage sensing, signaling and repair, as well in 
cellular growth and development (Shiloh, 2003; Melo and Toczyski, 2002).  
Three common motifs are shared amongst the structure of the human PIKK 
family members. First is the Frap, ATM, and TRRAP (FAT) domain. Second is the PI3K 
domain, which confers catalytic capability to the active kinases of the family members. 
Third is the FATC domain at the C-terminus, which is conserved amongst the members. 
The non–kinase domain portions of PIKKs could assist in the maintenance of the 
protein’s stability and interaction with other proteins. The exact function of these regions 
has yet to be uncovered, but mutations in certain protein sequences destabilize the protein 
(Shiloh, 2001a; Abraham, 2004a).  
Members of the family are very large proteins. DNA-PKcs  is a polypeptide of 
about 465 kDa, ATM is a homodimer of 370kDa and ATR runs at 300kDa on a SDS-
PAGE gel. All members are kinases except TRRAP (Abraham, 2004b). ATM, ATR and 
DNA-PKcs are the three well-known members of the PIKK family because of their 
involvement in regulating the cellular responses to DSBs (Abraham, 2001a). All three are 
Ser/Thr kinases, capable of phosphorylating substrate proteins with preference to the 
consensus sequence Ser/Thr-Gln.  
V.3.2 ATM/ATR activation:      
ATM and DNA-PKcs respond mainly to DSB, while ATR is activated by ssDNA 
and stalled DNA replication forks. ATR is also the main sensor activated under UV 
induced photo-damage of bases. External DNA synthesis replication blockade agents like 
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Hydroxyurea (HU) and Aphidicolin (APH) activate only ATR as well (Robison et al., 
2005).  
ATM is known to survey the DNA for DSBs. It was initially identified by 
positional cloning and was mapped on chromosome 11. The gene is organized into 66 
exons. ATM is mainly a nuclear protein in the form of dimers or multimeric complexes, 
with the kinase domain of one molecule bound to the other in an intermolecular 
interaction (McKinnon, 2004). However, upon exposure to adriamycin or IR induced 
DSBs, there is an alteration of the chromatin structures of the DNA double helix. This 
induces rapid intermolecular phosphorylation of ATM dimers on the residue Ser1981. 
The auto-phosphorylation in the FAT domain of the ATM protein leads to the 
dissociation of the previously inert dimer complex. As a result, active ATM monomers 
are then free to migrate to sites of DSBs and phosphorylate substrates such as p53 and 
cell cycle checkpoint protein kinase 2 (Chk2) (Hirao et al., 2000; Abraham, 2001a).  
The activation of ATM/ATR requires their recruitments to the sites of damage, 
the nuclear foci (Robison et al., 2005). Their recruitment to DNA lesions occurs by a 
common mechanism through an evolutionarily conserved motif at the C-terminus of 
these proteins, and this recruitment is required for PIKK-dependent DNA-damage 
signaling (Fernandez-Capetillo et al., 2003). ATR is recruited to ssDNA by the ATR 
interacting protein (ATRIP) and ATM by the C-terminus of Nijmegen Breakage 
Syndrome (Nbs1) (Kastan and Lim, 2000). 
V.3.3 Cellular events signaled by ATM/ATR:       
Although ATM/ATR and DNA-PKcs are activated in response to DNA damage, 
they perform different roles. DNA-PKcs-mediated phosphorylation of XRCC4 in vivo 
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may influence its activity in NHEJ (Zhou and Elledge, 2000; Khanna et al., 2001; Rouse 
and Jackson, 2002). Another substrate of DNA-PKcs is A2, a replication factor, 
suggesting that DNA-PKcs may have other cellular functions. On the other hand, 
ATM/ATR are involved in all cell cycle checkpoint control and repair. In addition, ATM 
can also trigger apoptosis in radiation treated cells. ATR partially overlap with ATM in 
terms of cellular functions, in detecting DNA damage. ATR is also found to be essential 
for the maintenance of the normal telomere length in human. However, they may have 
different substrate specificities. ATR’s main substrate is CHK1; ATM’s is CHK2 
(Shiloh, 2001b). 
V.3.3.1 Cell cycle checkpoints downstream of ATM/ATR:       
Arrest in cell cycle progression (from G1 to S entry or through S phase) in the 
presence of by DSBs provides extra time to allow DNA repair to occur (Zhou and 
Elledge, 2000). This delay happens before the damaged DNA nucleotides are encountered 
by a replicative DNA polymerase or passed to the daughter cell duplicated. Likewise, 
DNA lesions present in the G2 phase prevent entry into mitosis. This allows repair to 
happen before the mis-segregation of chromosomal fragments during cytokinesis and a 
resultant chromosomal aberration in daughter cells. Such pauses in cell-cycle progression 
are often termed `cell-cycle checkpoints' (Niida and Nakanishi, 2005). 
ATM interacts with a broad network of proteins, including checkpoint factors 
(Chk2), tumour suppressors (p53 and Brca1), DNA repair factors (RAD50, RAD51, 
GADD45), and other signaling molecules (c-Abl and NF-κB). ATM is recruited to and 
activated at sites of DNA DSBs. Activated ATM then initiates cell cycle arrest at the 
G1/S checkpoint mainly through phosphorylation of p53 at Ser15 (Abraham, 2001a). 
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Moreover, ATM also phosphorylates and activates Chk2, which can phosphorylate p53 at 
Ser 20 in humans (and Ser 23 in mouse) and stabilize the p53 protein. Meanwhile, ATM–
mediated phosphorylation of other DNA damage response proteins like Brca1, Nbs1 and 
Smc1 leads to a variety of effects on DNA repair, cell-cycle progression and apoptosis 
(Kitagawa et al., 2004) (Illustration 6). 
 
 
Illustration 6: The diagram shows some signaling cascades activated by ATM. 
Downstream cellular events resulted are arrest at all phases of the cell cycle (modified 
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On the other hand, ATR also plays an essential role in the maintenance of the 
genome integrity and cell viability (Durocher and Jackson, 2001). It functions in parallel, 
complementarily and cooperatively with ATM. Overall, numerous studies put ATM/ATR 
as crucial components of the DNA DSBs signaling cascades. At the beginning of these 
pathways is the formation of nuclear foci under DNA genomic assault.  
V.3.3.2 Foci signaling molecules:      
Nuclear foci are functional replicons or units of DNA repair machinery. Sensors, 
mediators, transducers, and effectors all assemble at the nuclear foci (Takahashi and 
Ohnishi, 2005). Therefore, nuclear foci function as centers of signal propagation to 
control cell cycle arrest or programmed cell death, downstream events after DNA damage 
(Fernandez-Capetillo et al., 2003). However, the exact function of nuclear foci in 
physiological conditions is still unknown. Only some foci proteins are discussed in 
relation to the project. ATM/ATR, MRN complex are some early proteins that assemble 
onto the nuclear foci and sense the damage at DSBs (Maser et al., 1997).                
H2AX 
H2AX is a minor form of the histone H2A protein. It is the earliest protein 
assembled onto the foci at sites of DSBs induced by IR. This DNA-binding protein is a 
target of both ATM and ATR. γ-H2AX, the phosphorylated form of H2AX at Ser139 is 
reflective of the generation of local DSBs in the nucleus. Furthermore, the protein 
functions in the recruitment of proteins that hold sister chromatids together, thus assisting 
in promoting error-free HRR mechanism over the error-prone NHEJ mechanism (Zhou et 
al., 2006; Takahashi and Ohnishi, 2005).  
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TopBP1 and Brca1 
Cells respond to DNA DSBs through the actions of signal-transduction cascades 
in which a `signal' (a DNA lesion) is detected by a `sensor' (DNA-damage binding 
proteins such as PIKK family members ATM/ATR) that then triggers the activation of a 
`transducer' system (protein kinase cascade such as Chk2/1 and p53 signaling) (Yu et al., 
2002). The system amplifies and diversifies the signal by targeting a series of 
downstream `effectors' (cell cycle regulators such as p21 and 14-3-3б) to result in the 
final DNA-damage response. The function of the mediators like TopBP1, Brca1 is 
believed to relay or propagate the signal from sensors to transducers (Zhang et al., 1998). 
They help in converting DNA damage into intracellular signals that control cellular 
behavior (Yamane et al., 2002).  
Both TopBP1 and Brca1 are BRCT-containing proteins. Other BRCT-containing 
proteins include Brca2 and Rad9. All of them are involved in DNA damage responses. 
Rad9 is one of the components of the (RAD9-RAD1-HUS1) 9-1-1 complex that also 
assembles on the nuclear foci (Melo and Toczyski, 2002). c-Abl was known to physically 
interact with both TopBP1 and Brca1 (Zeng et al., 2005). It plays a dual antagonistic role 
with TopBP1 such that c-Abl and TopBP1 inhibit each other’s activity. Brca1 is essential 
in strand invasion of HRR of DSBs. Cells deficient for Brca1 show defects in the HRR 
mechanism. The BRCT motif, common to TopBP1, Brca1, Brca2 and Rad9, was shown 
to play a vital role in nuclear foci formation and proper signal propagation from there (Au 
and Henderson, 2005; Kobayashi et al., 2002). The BRCT motif of Brca2 was shown to 
directly interact with RAD51 protein and affects the RAD51 foci formation at DSBs sites. 
It probably exerts an effect on the nuclear localization and DNA binding properties of 
RAD51. 
                                                                       Chapter 1-Introduction Part V; DNA damage 
 56
RAD51 
Rad51, an E.coli RecA homologue, is required for DNA homologous 
recombination and repair. It is localized at a different foci position from the MRN 
complex, but close to the break caused by DSBs (Aguilera, 2001). RecA is reported to 
form a structured nucleoprotein complex with single-stranded DNA and this assists in 
strand exchange between sister chromatids in homologous recombination. Similarly, 
Rad51 and other associated Rad family proteins are essential in HRR mechanism of 
DSBs (Daboussi et al., 2002). c-Abl was known to physically interact with RAD51, 
tyrosine phosphorylates it in vivo and in vitro, in an ATM dependent manner. c-Abl thus 
functionally inhibits the strand exchange activity with the homologous sister chromatids 
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Chapter 2: Materials and Methods 
2.1 Cell cultures 
2.1.1 Osteoblast isolation 
An enzyme solution consisting of 0.1% Collagenase and 0.2% Dispase in α–
MEM was prepared and filtered. Calvaria were extracted from newly born (1 or 2 day 
old) mice, and rinsed in ice–cold PBS to remove blood. These were then transferred to 
15ml falcon tubes, and 0.2ml of the enzyme solution was added to each tube, which was 
then placed at 37°C, and agitated at 150 cycles/min for 15 minutes. The supernatant from 
the first agitation (fraction I) was discarded. 0.2ml of the fresh enzyme solution was 
added to the tube and the procedure was repeated. The resulting fraction was removed 
and placed on ice (fraction II). This digestion was repeated twice to give fractions III and 
IV. In the final digest, the digestion was carried out for 30 minutes. The last fraction (V) 
was also removed and placed on ice. All the fractions from II to V were combined and 
centrifuged at 1500rpm for 5 minutes at 4°C. The resulting cell pellet consisting of 
osteoblasts and some bone debris was resuspended in 3ml of α–MEM media with 15% 
FBS, and plated in 6–well plates. Media was changed after one week to remove bone 
debris. The osteoblast cells were grown undisturbed to allow them to proliferate. Once 
confluent, the cells were trypsinized, counted, and plated for experimentation.  
2.1.2 Stromal cell isolation 
Osteoblast progenitor cells were isolated from the bone marrow of 3 to 4 month 
old mice.  The femurs and tibias were extracted and cleaned using a scalpel, and washed 
in PBS a few times. After removing the epiphyses and gaining access to the marrow 
cavities, whole bone marrow was flushed out using a 10ml syringe fitted with a 261/2 
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gauge needle, filled with α-MEM media. The marrow samples were mechanically 
disrupted by repeated aspiration using the same syringe. The resulting cell suspension 
was centrifuged at 1300 rpm for 5 minutes at 4°C, and the pellet resuspended in α-MEM 
media with 15% FBS. The resuspended cells were counted and plated as required. 
2.1.3 Monocyte isolation 
Osteoclasts were isolated from the bone marrow cell suspension (obtained as 
mentioned above). One part of Ficoll–Hypaque M solution was carefully pipetted on top 
of two parts of the stromal cell suspension in a 5ml round–bottom polystyrene tube. This 
tube was then centrifuged at 500g for 20 minutes at 4°C, with centrifuge brakes shut off. 
There were very distinct layers of the cell suspension after centrifugation. At the very top 
layer was a pale yellow plasma layer. The mononuclear cells were present as a white 
band just below the plasma layer. This band separated the plasma from the Ficoll. The 
mononuclear layer was carefully drawn off using a pipette and transferred to another 
polystyrene tube. This cell suspension was diluted at least 1:4 with 1X PBS and 
centrifuged at 500g for 5 minutes at 4°C. The wash step was repeated three times until 
the supernatant was clear. The remaining cells were resuspended in α-MEM media with 
15% FBS, counted, and plated.  
2.1.4 Mouse embryonic fibroblast (MEF) isolation 
The pregnant female is sacrificed at day 13p.c. by cervical dislocation; embryos 
are taken out and placed into a petri dish containing PBS. Head and internal organs were 
removed; the body was washed with fresh PBS to remove as much blood as possible. 
Embryos are finely minced until they become "pipettable" and were resuspended in 
trypsin-EDTA (about 1-2ml per embryo, Gibco 25300-096) and incubated with gentle 
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shaking at 37°C for 15min. Ideally, the resulting cell suspension should be essentially 
free of any larger pieces of tissue and should not be too viscous. The suspension was 
transferred to a new 6 cm tissue culture dish and cultured in 4ml of fresh DMEM (high 
glucose, Gibco 41966-052) with 10% (v/v) FCS,1/100 (v/v) L-glutamine (200mM: Gibco 
25030-024) and1/100 (v/v) pen/strep (Gibco 15140-122) until confluency.  
2.2 Osteoblast and Osteoclast Differentiation Assays 
2.2.1 Alkaline phosphatase (ALP) qualitative staining assay 
Calvarial osteoblasts were plated at a density of 2.5x104 cells/well in 12–well 
plates. For Colony Forming Unit (CFU) determination, the total bone marrow cells were 
plated at 5x106 cells/well in 6–well plates. The cells were cultured for different time 
periods, to assess progressive ALP expression. At each time point of day 1, day 7 and day 
10, a calvarial plate was collected. CFU plates were collected at day 6, day 8, day 10 and 
day 12. These plates were stained for ALP expression according to the protocol described 
in the Sigma–Aldrich Alkaline Phosphatase kit. Stained plates were later photographed. 
The numbers of CFUs in each well was determined by visual counting.  
2.2.2 ALP quantitative liquid assay 
Calvarial osteoblasts were plated at a density of 2.5x104 cells/well in 12 – well 
plates. The cells were cultured for different time periods, and harvested at each time point 
of day 1, day 7 and day 10. Media is removed from the cell layer and cells are washed 
twice with Tris buffer (50mM, pH7.5). 500μl of Tris buffer (50mM, pH7.5) was added to 
each well and the cells were scraped off. The cell suspension was transferred to an 
Eppendorf tube and sonicated for 20 seconds. The samples were frozen at –20°C till use. 
The assay buffer was made using 1.5M Sigma 221 (2-amino-2-methyl-1-propanol) and 
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1M MgCl2. 700μl of the former was added to 100μl of the latter and topped up to 10ml 
with dH2O. Substrate solution was made by reconstituting 10mM nitrophenyl-phosphate 
in the assay buffer (37.6mg/10ml assay buffer). Empty tubes were first chilled by placing 
in an ice bath. Equal volumes of samples, assay buffer, and substrate were added into 
each tube. Tris buffer was used in the blank sample. The tubes were then transferred to a 
37°C water bath. When the samples turned at least a pale shade of yellow, the reaction 
was stopped by adding 6X volume of 0.3M NaOH, and time taken for this reaction was 
recorded. The reaction solution was transferred to cuvettes and absorbance read at 
405nm. Protein concentration was determined by the BioRad method. The relative ALP 
activity is defined as milli-moles of p-nitrophenol phosphate hydrolyzed per minute per 
milligram of total protein (units). 
2.2.3 Von Kossa mineralization assay 
Calvarial osteoblasts were plated at a density of 2.5x104 cells/well in 12–well 
plates. After plating, cells were switched to medium supplemented with ascorbic acid 
(50μg/ml) and β-glycerolphosphate (10μM) to help collagen deposition and 
mineralization. Mineralization is a relatively late process, so the plates were only 
harvested at day 21 and 28. The plates were washed three times with Tris buffered saline 
(20mM in 0.9%NaCl, pH7.4), fixed in 4% Neutral Buffered Formalin for 5 minutes, then 
washed with dH2O thrice. 5% Silver Nitrate solution was prepared in dH2O, added to the 
wells to cover the cell layer, and exposed to UV light for 1 hour. Silver nitrate solution 
was removed and the plates washed with dH2O thrice. 5% Sodium thiosulphate solution 
in dH2O was added to the wells for 2 minutes.  
                                                                                          Chapter 2-Materials and Methods 
 61
2.2.4 Tartrate-resistant alkaline phosphatase assay 
Bone marrow monocytes were extracted as stated earlier, and plated at a density 
of 7.5x104 cells/well in 96–well plates. The cells were cultured for different time periods 
in 15% α–MEM media supplemented with 30ng/ml M-CSF and 50ng/ml RANKL to aid 
osteoclast differentiation. At each time point of day 7, day 8 and day 10, a plate was 
harvested for TRAP staining according to the protocol specified in the Sigma–Aldrich 
alkaline phosphatase kit. Stained plates were later photographed. The numbers of TRAP+ 
cells in each well was determined by visual counting.  
2.2.5 Pit formation assay 
Osteoclasts were extracted as stated earlier, and were grown in 24–well plates in 
15% α–MEM media supplemented with 30ng/ml M-CSF and 50ng/ml RANKL for 2 to 3 
days until they start to fuse. Before use, the dentine discs were pre–soaked in PBS 1X for 
a few hours, and then soaked in media for 15 minutes. Osteoclasts were trypsinized for 
15 minutes, collected, resuspended in media and counted. They were plated at a density 
of 7.5x104 cells/well in 96 – well plates. The osteoclasts were allowed to resorb for at 
least 4 days. After culturing the osteoclasts for various time periods, the discs were rinsed 
in 1M NH4OH to remove the cells, and sonicated for 30 seconds. The discs were further 
rinsed twice in water, and stained in Gill’s Hematoxylin for 2 minutes. The excess stain 
was rubbed off using a rough cloth, such that only the pits remained dark. The dentine 
discs were photographed under microscope.   
2.2.6 Urinary Pyridinium assay 
Mice were starved overnight, and urination induced by massaging the lower 
abdomen. The expelled urine was immediately transferred to Eppendorf tubes and was 
stored at -20°C until use. Urine samples were assayed for pyridinium crosslinks with 
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METRA PYD EIA kit, following the protocol specified by the manufacturer.  The 
pyridinium levels were normalized to the urine levels of creatinine. The relative 
pyridinium was measured as Pyridinium (nM)/ Creatinine (mM).  
2.3    Molecular biology   
2.3.1 Western blot analysis  
Cells were washed with cold PBS and lysed in TNEN buffer (50mM Tris, 150 
mM NaCl, 5mM EDTA, 0.5% NP-40, 0.1% Triton X-100) supplemented with 1mM NaF, 
Na2VO3, 1mM PMSF, 1 µg/ml of aprotonin, leupeptin, and pepstatin. Protein 
concentration was determined using the Bio-Rad assay. Proteins were resolved by SDS-
PAGE and transferred to polyvinylidene difluoride membranes (PVDF, Millipore).  Anti-
osterix was generated by injecting rabbits with a synthesized peptide (Biogenes).  Anti-
p53 and anti-p19 antibodies were purchased from Oncogene; anti-p21 antibodies 
purchased from BD Pharmingen; anti-p16 and anti-p27 antibodies from Santa Cruz; and 
anti-actin antibodies from Sigma.  
Antibodies 
 
Primary Antibodies  Dilution Secondary Antibody 
P-p53 ser15(Cell Signaling) 1:1000 α-rabbit polyclonal 
ß-actin(Sigma-Aldrich) 1:5000 α-mouse monoclonal 
p21(Cell Signalling) 1:1000 α-mouse monoclonal 
p19 (Santa Cruz) 1:1000 α-rabbit polyclonal 
p16 (Santa Cruz)  1:500 α- rabbit polyclonal 
p27 (Santa Cruz) 1:1000 α-mouse monoclonal 
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Chk1 (Cell Signalling) 1:1000 α-rabbit polyclonal 
Chk2 (Cell Signalling) 1:1000 α-rabbit polyclonal 
P-Chk 1(ser345) (Cell Signaling) 1:1000 α-rabbit polyclonal 
P-Chk2(thr68) (Cell Signaling) 1:1000 α-rabbit polyclonal 
Cdk4/ cdk6 (Cell Signalling) 1:1000 α-mouse monoclonal 
Erk 1 (Santa Cruz) 1:1000 α-rabbit polyclonal 
Pkc-δ (Cell Signalling) 1:1000 α-rabbit polyclonal 
TopBP1 (Biomed Diagnostics) 1:500 α-mouse polyclonal 
BRCA1 (Calbiochem) 1:1000 α-mouse polyclonal 
53BP1 (Calbiochem) 1:1000 α-rabbit polyclonal 
ATM (Calbiochem) 1:1000 α-rabbit polyclonal 
Rad51 (Santa Cruz) 1:1000 α-goat polyclonal 
ATR (Santa Cruz) 1:500 α-rabbit polyclonal 
H2AX (BETHYL Lab, Inc) 1:1000 α-rabbit polyclonal 
Mre11 (Novus Biological) 1:1000 α-rabbit polyclonal 
phosphor-ATM1981 (Rockland) 1:1000 α-rabbit polyclonal 
c-Abl  (Oncogene) 1:1000 α-mouse polyclonal 
PY20 (BD transduction Lab.) 1:1000 HRP conjugated 
p38 (Cell Signalling) 1:1000 α-rabbit polyclonal 
 
2.3.2 Luciferase assay 
The osterix promoter (fragments of 0.13-6.0 kb from the start of transcription) 
was cloned into pGL3 (luciferase basic vector) (Promega).  Increasing amounts of p53 
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expression constructs, the promoter plasmid (pGL3-Osx-Luc), and renilla plasmid 
(internal control) were co-transfected into C2C12 or MC3T3-E1 cells. Cells were 
harvested 24 hours later, washed with PBS, and lysed with reporter lysis buffer 
(Promega). The luciferase activities were measured following the manufacturer’s 
procedures and were normalized against the renilla activity.  All transient expressions in 
this assay were carried out in triplicates. 
2.3.3 Knocking down of osterix 
For siRNA knocking down experiments, the following siRNA oligomers 
(Dharmacon) were used: siGENOME on-target duplex (1), sense: GCC AUA CGC UGA 
CCU UUC AUU; siGENOME on-target duplex (2), sense: GGG CAC AGC UCG UCU 
GAC UUU; siGENOME on-target duplex (3), sense: CAA CAC ACC UAC UCC UUG 
GUU; siGENOME on-target duplex (4), sense: GCA GGC AUC UCA CCA GGU CUU. 
The control siRNA oligomer used was a non-targeting negative siRNA control pool. 
They were transiently transfected into primary osteoblasts following the manufacturer’s 
procedures (Dharmacon), after 3 days, cells were harvested for ALP, osteocalcin and 
Western blot analysis.  
2.3.4 Retroviral infection of cells 
To express osterix in osteoblasts, a retroviral vector was constructed with osterix 
ORF cloned into the pMSCVpuro vector (BioMed Diagnostic).  Retroviral constructs 
encoding osterix, p21, p53 and GFP were used to transfect Plat E packaging cell line 
using FUGENE. After 2 days, media containing the transfected cells were collected and 
directly used for infection of primary osteoblasts at early passages. Osteoblasts were then 
selected against puromycin for 2 or 7 days. Expression of the virus-encoded proteins was 
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confirmed by Western blot analysis. For ectopic expression of osterix, osterix retroviral 
supernatant (different dilutions) was then used to infect primary cells, followed by 3 
days’ selection against 5ug/ml of puromycin before being harvested for Western blot, 
ALP, and RT-PCR assays. Judged by GFP (expressed in the virus), the minimum amount 
of retroviral supernatant that can infect ≥80% of the cells was set at 100%.  To express 
osterix to different levels, different dilutions (50, 100, 150, and 200%) of retroviral 
supernatant were used.   
2.3.5 RNA extraction 
TRIzol reagent was used in RNA extraction following the protocol specified by 
the manufacturer. In cases where whole tissue was used, the samples were homogenized 
in 1ml of TRIzol using a glass homogenizer. Briefly, the cells were washed with cold 
PBS and TRIzol added. The cells were lysed by scraping and passing through a pipette 
several times. The cell suspension was kept on ice at all times, except when specified in 
the protocol. The resulting RNA pellet was dissolved in 20 to 40μl of DEPC water, 
depending on its size. RNA measurement was conducted by measuring UV absorbance at 
260 nm and 280 nm. Calculation of the RNA concentration was based on the absorbance 
at 260 nm and RNA purity was judged as the 260 nm/280 nm ratio. RNA samples were 
stored at –80°C till use. 
2.3.6 Reverse transcription (RT) and cDNA preparation 
Total RNA was isolated from cells or calvaria, which was frozen at -80oC and 
thawed for RNA extraction. Total RNA was subjected to DNase treatment (Ambion) and 
quantitated. Reverse transcription (RT) of total RNA to cDNA was carried out using the 
AMV Reverse Transcription system from Roche. 3 to 5 μg of RNA was used for each RT 
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reaction in a volume of 20μl. The cDNA was stored at –80°C till use. The RT – cDNA 
was subjected to PCR amplification of genes of interest using the following primers. 1 to 
2μl cDNA was sufficient for each amplification reaction.  
Primer pair Sequence 
Actin (Forward) 
Actin (Reverse) 
5`- AGA TGT GGA TCA GCA AGC AG -3` 
5`- GCG CAA GTT AGG TTT TGT CA -3` 
M-CSF (Forward) 
M-CSF (Reverse) 
5`- CTG GAA GGA GGA TCA GCA AG -3` 
5`- ATG TCT GAG GGT CTC GAT GG -3` 
Osteoprotegerin (Forward) 
Osteoprotegerin (Reverse) 
5`- CTG CCT GGG AAG AAG ATC AG -3` 
5`- TTG TGA AGC TGT GCA GGA AC -3` 
Osterix (Forward) 
Osterix (Reverse) 
5`- CCC CCA AGT GGC CCT AAG -3` 
5’- GGC TCA GAT CTC TAG CAG GTT -3` 
RANK-L (Forward) 
RANK-L (Reverse) 
5`- CAG AAG ACA GCA CTC ACT GC -3` 
5`- ATG GGA ACC CGA TGG GAT GC -3` 
RUNX2 (Forward) 
RUNX2 (Reverse) 
5`- CGT CAG CAT CCT ATC AGT TCC -3` 
5`- TGC CGC TAG AAT TCA AAA CA -3` 
 
2.3.7 Polymerase Chain Reaction (PCR) 
PCR was carried out for 30 cycles of denaturation (94oC/30second), annealing 
(57oC/30second), extension (72oC/1min), and 1 cycle of final extension (72oC/10min), 
which was just enough to detect the PCR products of osterix and Runx2. The detection 
and quantification of target mRNA were performed with semi-quantitative RT-PCR. The 
amplification for each mRNA was performed in the linear range for RT-PCR by 
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optimizing the template concentration and limiting the amplification cycles to below 30 
to ensure exponential amplification.  
2.3.8 Real- time PCR 
cDNAs obtained from osteoblast cells and calvaria of p53-/- and wild type mice 
were used in the presence of specifically designed osterix primers in a 20ul reaction mix 
with TaqMan MGB probe (FAMTM dye-labeled). The osterix expression levels were 
normalized by GAPDH as an internal control in real-time PCR analysis according to the 
manufacturer’s instructions (Applied Biosystems).   
2.3.9 Quantitation of RT-PCR and Western blot results 
RT-PCR (negative images of gels) or Western results were scanned with a 
Molecular Dynamics scanning densitometer. The relative levels of mRNA or protein of 
interest were then determined by measuring the intensity of the corresponding bands. All 
values were averages of cell cultures isolated from at least three p53-/- mice and their 
control littermates and were normalized to levels of the housekeeping genes such as 
GAPDH or actin.   
2.3.10 In situ hybridization 
α-S35-UTP labeled single-stranded RNA probes were prepared using a RNA 
labeling kit (DAKO) following the manufacturer’s procedure with slight modifications. A 
200bp mouse osterix cDNA fragment was used to generate antisense and sense probes. 
Hybridization was carried out as follows: after post-fixation in 4% paraformaldehyde-
PBS, sections were incubated for 2x15 min in PBS containing 0.1% active DEPC 
(Fluka), and equilibrated for 15 min in 5x SSC (NaCl 0.75M, Na-Citrate0.075M). The 
p53-/- and control bone sections were then prehybridized for 2 h at 58°C in the 
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hybridization mix (50% formamide, 5x SSC, salmon sperm DNA 40µg/ml; 500 µl on 
each section). The osterix anti-sense and sense probes were denatured for 5 min at 80°C 
and added to the hybridization mix (400 ng/ml). The hybridization reaction was carried 
out at 58°C for 4 h with 20 µl of hybridization mix on each section, covered by a 
rectangle of Parafilm (American National Can). Prehybridization and hybridization were 
performed in a box saturated with a 5x SSC–50% formamide solution to avoid 
evaporation. After incubation, the sections were washed for 30min in 2x SSC (room 
temperature), 1 h in 2x SSC (65°C), 1 h in 0.1x SSC (65°C), and equilibrated for 5 min in 
Buffer 1 (Tris-HCl 100 mM and NaCl 150 mM, pH 7.5). The sections were then 
incubated for 2 h at room temperature with alkaline phosphatase-coupled anti-
digoxigenin antibody (Boehringer Mannheim) diluted 1:5000 in Buffer 1 containing 
0.5% blocking reagent (Boehringer Mannheim). Excess antibody was removed by two 15 
min washes in Buffer 1, and the sections were equilibrated for 5 min in Buffer 2 (Tris-
HCl 100mM, NaCl 100mM, and MgCl2 50mM, pH 9.5). Color development was 
performed at room temperature (30 min to 3 days, depending on the amount of transcripts 
to be detected) in Buffer 2 containing NBT and BCIP (Boehringer Mannheim). Staining 
was stopped by a 10 min wash in Tris/EDTA (10/1mM, pH 8.0), and non-specific 
staining was removed O/N in EtOH 95% with gentle agitation. Sections were rehydrated 
for 15 min in deionized water to remove the precipitated Tris and then dehydrated 
through successive baths of EtOH (70, 95, and 100%) and xylol (2 x 15min each), and 
mounted in Eukitt resin (O. Kindler GmbH & Co.). 
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2.3.11 Northern blot analysis of osteocalcin mRNA 
For Northern Blot analysis, cells were collected, and total RNA was isolated using 
TRIzol. RNA was quantitated at OD260 using a spectrophotometer. Ten micrograms of 
total RNA were fractionated onto a 1.5% formaldehyde agarose gel, transferred to Nytran 
membrane (Schleicher Inc., Keene, NH). Membrane filters were rinsed with 2x standard 
saline citrate and cross-linked under UV light. The membrane was then hybridized with 
RNA probes prepared from osteocalcin cDNA in a hybridization solution (50% 
formamide, 5x SSC, salmon sperm DNA 40µg/ml), washed in 2x SSC (room 
temperature) for 30 min and then in 0.1x SSC (65°C) for 20 min, and exposed to X-ray 
films for developing.  
2.3.12 Chromatin immunoprecipitation assay 
C2C12 cells were cultured in 10cm tissue culture dish at 4-6 x 106 cells/ml. 1/10 
volume of 11% formaldehyde solution was added to the culture (final concentration, 1%), 
which was incubated for 10 min at 26°C with gentle shaking. The cell culture was chilled 
in ice water bath for 50 min with occasional shaking and pelleted by centrifugation at 
1000g at 4°C for 5 min. The cell pellet was resuspended in 500 µl of ice-cold buffer 
containing protease inhibitors (1 mM PMSF and 1/100 volume of Trasylol), and vortexed 
vigorously for 30 s and chill on ice for at least 1 min to cool down. The cells were further 
sonicated for 30 s, four times with a Sonifier 450 sonicator (Branson; output 3.0, duty 
cycle 30%) on ice. There should be at least a 1-min interval on ice between each pulse in 
order to cool the sample. This sonication step shears the chromatin DNA to sizes ranging 
between 0.5 and 1.0 kb. The sizes of the sheared DNA can be confirmed by 2% agarose 
gel electrophoresis stained with ethidium bromide. Immunoprecipitation of p53 was then 
carried out followed by purification of the coimmunoprecipitated DNA and PCR 
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amplification of the coimmunoprecipitated DNA for osterix. The sequences of primers 













2.3.13 Plasmid construction  
Osterix and p21 DNA inserts were subcloned into pMSCV retroviral vector. 
p53Ser15A was made by site-directed mutagenesis. The wild type p53 plasmid DNA was 
denatured at 92 degrees to produce single strands. A synthetic oligonucleotide flanking 
the p53ser15 region with the Serine to Alanine mutation was annealed at 54 degrees to 
the target region. Extending this mutant oligonucleotide using the wild type p53 plasmid 
DNA strand as the template at 68 degrees in PCR reactions and the final p53SerA 
construct DNA was propagated by transformation in E. coli.  
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2.4 Biochemistry Techniques 
2.4.1 Treatment of Cells with DNA-damaging Agents 
Cells were treated with different drugs for different time periods. Drugs used 
include: hydroxyurea, aphidicolin, cisplatin (CDDP) and adriamycin. Another method of 
inducing DNA damage was γ-irradiation.  Cells were γ-irradiated at 5-30Gys, waited for 
5 min-30hrs before being harvested for Western blot analysis. 
Information on drug used 
Hydroxyurea belongs to the group of medicines called anti-metabolites. It is used 
to treat certain kinds of cancer and to prevent painful episodes associated with sickle cell 
anaemia. Hydroxyurea seems to interfere with the growth of cancer cells, which are 
eventually destroyed. Hydroxyurea inhibits DNA synthesis without inhibiting 
RNA/protein synthesis by blocking ribonucleotide reductase. It is used as a radiation 
sensitizer and is specific for S phase of cell cycle but may also arrest in G1. 
Cisplatin /CDDP (cis-diamminedichloroplatinum) belongs to the group of 
medicines known as alkylating agents. It is used to treat cancer of the bladder, ovaries, 
and testicles. It may also be used to treat other kinds of cancer. Cisplatin interferes with 
the growth of cancer cells, which are eventually destroyed. CDDP binds with DNA, 
RNA, or other macromolecules at two sites to form interstrand and intrastrand links. It 
causes covalent DNA cross links and strand breaks. 
Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication. 
Aphidicolin is defined as Tetracyclic diterpene with antiviral and antimitotic properties. It 
is a specific inhibitor of (alpha)-type polymerase (eukaryotic and viral coded) and blocks 
DNA synthesis by acting as a DNA polymerase inhibitor.  
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Adriamycin/Doxorubicin belongs to the group of medicines known as 
antineoplastics. It is used to treat cancers of the blood; lymph system; bladder; breast; 
stomach; lung; ovaries; thyroid; nerves; kidneys; bones; and soft tissues, including 
muscles and tendons. It may also be used to treat other kinds of cancer. Doxorubicin 
seems to interfere with the growth of cancer cells, which are then eventually destroyed by 
the body. Doxorubicin also affects topoisomerase II, an enzyme responsible for DNA 
strand breaks during transcription. Doxorubicin stabilizes the initial DNA-enzyme 
complex leading to double-strand DNA breaks. Doxorubicin complexes with DNA by 
intercalating between DNA base pairs, causing the helix to change shape. This simple act 
of changing the conformation of DNA can interfere with strand elongation by inhibiting 
DNA polymerase and can inhibit protein synthesis due to effects on the RNA 
polymerase. 
2.4.2 Genomic DNA Isolation 
DNA was extracted using Genomic DNA Isolation Kit (BioVision). Cells were 
scraped and collected in PBS. Cell lysis buffer was added to lyse cells. After 
centrifugation, supernatant was removed and pellet was resuspended in cell lysis buffer 
containing Enzyme B Mix (provided in the kit). The mixture becomes clear after 
incubating mixture for 1 hour in 50ºC water bath. Phenol/chloroform was added to 
remove insoluble materials. Ethanol precipitation was then carried out to obtain DNA 
using absolute/100% ethanol. The DNA was then washed twice using 70% ethanol, and 
dissolved in RNase free water. 
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2.4.3 Immunofluorescence 
For single or double labeling, cells were grown overnight on glass cover-slips, 
subjected to adriamycin treatment, and were fixed with 4% paraformaldehyde and 
permeabilized with 0.1% Triton X-100 for 20 min. After blocking with 5% BSA in PBS 
for 30min, the cells were incubated with primary antibodies in 1% BSA for 60 min, 
followed by incubation for 1h with Texas Red-conjugated anti-mouse or anti-rabbit IgG 
(Molecular Probes Inc.). The coverslips were mounted in Vectashield mounting medium 
(Vector Laboratories) and the images were captured on a Zeiss confocal microscope 
(Axioplan 2 imaging system).  
2.4.4 Cell viability analysis 
To measure cell death rates, cells were cultured in 96 well plates at 1x104/well, 
and then treated with IR or adriamycin for different periods of time. Cell proliferation 
reagent WST-1 (Roche) was added to each well and the cells were further incubated for 
an hour at 37ºC. The absorbance was measured against a background control by 
microplate (ELISA) reader at 430 nm. The reference wavelength is 650nm. Trypan blue 
exclusion assays were used to confirm the results obtained from this quantitative assay.  
Cells were collected by pooling cells from the culture medium as well as the trypsinized 
adherent cells.  Dead cells were counted by the trypan blue exclusion method.  
2.4.5 Cell cycle analysis 
2.4.5.1 Flow Cytometry 
Cells were trypsinized, washed with PBS and fixed in 100% ethanol overnight at -
20 degrees. Ethanol was removed by centrifuging and washing once with PBS. Cells 
were then stained with 50ug/ml of Propidium Iodide and 100ug/ml of RNase A was 
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added to breakdown RNA. Cells were assayed for their DNA content by using a flow 
cytometer. Area of each peak was calculated to come up with G1/S and G2/M results. 
 
2.4.5.2 Radio-resistant DNA synthesis (RDS assay)  
Inhibition of DNA synthesis after irradiation or adriamycin treatment was 
assessed. Briefly, cells in the logarithmic phase of growth were pre-labeled by culturing 
in DMEM containing 10 nCi of [14C] thymidine (Amersham Biosciences) for 
approximately 24 h; this pre-labeling provides an internal control for cell number by 
allowing normalization for total DNA content of samples. The medium containing [14C] 
thymidine was then replaced with normal DMEM containing 10% FBS, and the cells 
were incubated for another 24 h. Cells were irradiated or treated with adriamycin, and 
then pulse-labeled with 2.5 µCi of [3H] thymidine (Amersham Biosciences)/ml for 2hr. 
Cells were harvested, washed twice with PBS, and fixed in 70% methanol for at least 
30 min. After that the cells were transferred to Whatman filters and fixed sequentially 
with 70% and then 95% methanol, the filters were air dried and the amount of 
radioactivity was assayed in a liquid scintillation counter. The resulting ratios of 3H 
counts per minute to 14C counts per minute, corrected for those counts per minute that 
were the result of channel crossover, were a measure of DNA synthesis and intra-S 
checkpoint.  
2.4.5.3 Immunofluorescent detection of phosphorylated histone H3 
(Ser10) 
Cells, treated with IR or adriamycin, were harvested, washed with PBS, and fixed 
in suspension (concentration, 106 cells per ml) by the addition of 0.25-0.5% formaldehyde 
in PBS for 10min at 37°C. The cells were then washed twice with PBS, permeabilized in 
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ice-cold 90% methanol, and then incubated on ice for 30 min. After centrifugation, the 
cell pellet was suspended in 100 µl of PBS containing 1% bovine serum albumin (BSA) 
and 1:50 dilution of a polyclonal antibody that specifically recognizes the phosphorylated 
form of histone H3 (Cell Signaling Cat. #9706) and incubated for 3 h at room 
temperature. The cells were then rinsed with PBS containing 1% BSA and incubated with 
fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin G antibody (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, Pa.) diluted at a ratio of 1:100 in PBS 
containing 1% BSA. After 30 min of incubation at room temperature in the dark, the cells 
were washed again, before the fluorescence was measured. Cellular fluorescence was 
measured at an emission wavelength of 525nm by using a Becton Dickinson 
FACSCalibur flow cytometer (San Jose, Calif.). 
2.4.6 DNA repair 
2.4.6.1 Single cell gel electrophoresis (Comet) assay 
MEFs were plated at 4.5 X105 cells per 35 mm2 tissue culture dish and irradiated 
at 2.5Gy. The cells and untreated cells were harvested and trypsinized after 30min or 
24hrs of IR, washed in ice cold phosphate-buffered saline buffer (1xPBS) and suspended 
in HBSS with 10% DMSO with EDTA. The cells were then resuspended in melted low 
melting point agarose (0.75%) (at 42°C) and immediately pipetted onto the comet slides 
(Trevigen). Cells were lysed in prechilled lysis solution at 4°C for 60 minutes. Alkaline 
unwinding was done at pH>13 for 40 minutes. Alkaline electrophoresis (25V, 300mA for 
20minutes) in alkaline solution (pH>13) was performed to detect the double and single 
stranded breaks. Neutral electrophoresis (25V for 10 minutes) was performed using 
1xTBE buffer to detect double stranded breaks. After electrophoresis, slides were briefly 
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rinsed in neutralization buffer (500 mM Tris-HCl, pH 7.5), dehydrated in 70% ethanol, 
air-dried and stained with SYBR green dye. The tail moment of the comets was generated 
using the Metasystems (Germany) analysis software ‘Comet imager version 1.2’. Fifty 
randomly chosen comets were analyzed per sample. The extent of DNA damage 
observed was expressed as tail moment, which corresponded to the fraction of the DNA 
in the tail of the comet. 
2.4.6.2 Quantification of Apurinic/apyrimidinic (AP) sites 
MEFs were plated at 4.5 X105 cells per 6cm tissue culture dish, they were then 
irradiated or treated with adriamycin for various periods of time and cells were collected 
for genomic DNA isolation using Genomic DNA isolation Kit (Biovision, Cat #K281-
50). AP sites were determined using a DNA Quantification Kit (Biovision, Cat#K253-
25). Briefly, 5ug of genomic DNA was mixed with 5ul of Aldehyde Reactive Probe 
(ARP) reagent and incubated at 37°C for 1 hour to tag the DNA AP site. ARP reacts 
specifically with an aldehyde group which is the open ring form of the AP sites. TE and 
Glycogen were then added to the reaction solution and ethanol precipitation was used to 
precipitate the AP-site tagged DNA. This ARP-labeled genomic DNA pellet was 
dissolved in TE buffer and together with 6 tubes of ARP-DNA standards supplied, they 
were added onto a 96-well microplate in triplicates. DNA binding solution was then 
added to each well and the plate was kept at room temperature overnight to allow binding 
of tagged-DNA to the plate surface. Following 5 times of washing, HRP-Streptavidin 
solution was added and the plate was shaken for 1 hour. HRP developer was lastly added 
to each well and incubated at 37°C for 1 hour before a colorimetric detection of 
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peroxidase conjugated to the avidin at 650nm to determine the number of AP sites per 
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Chapter 3: Results to Part I 
3.I.1 Rational and objectives of research to part I 
p53 is a tumour suppressor as it is mutated in more than half of primary human 
tumors (Vogelstein et al., 2000; Ko and Prives, 1996). Its major role is to promote cell 
cycle arrest, programmed cell death, and cell senescence. p53 is a master regulator of cell 
cycle checkpoints and apoptosis. Since all cells including chondrocytes and osteocytes 
eventually enter the ultimate stage of programmed cell death (Roach, 1997), it would be 
plausible to think that p53 could play important roles in function of osteoblasts. 
Furthermore, accumulating evidence suggest that p53 functions may be critical during 
development of various tissues and organs (Armstrong et al., 1995). Moreover, my 
laboratory focuses on aspects of developmental biology relating to signaling cascades 
centered around c-Abl (Druker and Lydon, 2000). It was found previously that this 
tyrosine kinase c-Abl is a positive regulator of bone remodeling. It enhances murine 
osteoblast differentiation. Previous studies showed a physical and genetic interaction 
between c-Abl and p53 (Sionov et al., 2001). Hence, I decided to study whether p53 
plays a role in osteoblast differentiation and mouse bone development. 
p53-/- mice were obtained from the Jackson laboratory and were crossed to 
C57BL/6 mice at least 6 times to obtain an almost homogenous background. For my 
studies, I used 3-4 months old mice as p53-/- mice develop tumors at a later stage of about 
5-6 months.  
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3.I.2 Defects in bone homeostasis in p53 knockout mice and culture 
3.I.2.1: p53-/- mice showed increased bone mass and increased bone formation  
No evident abnormality was observed in the gross development of the skeleton. 
Histological analysis of Haematoxylin & Eosin (H&E) stained long bone sections 
indicated that the growth plates were not significantly altered either (Fig. 1A).  However, 
dual x-ray absorptometry analysis of eight p53-/- mice and their littermate controls 
revealed that p53-/- mice showed a modest but consistent increase in the bone mineral 
density (Fig. 1B).     
 
 





Figure 1. Mice deficient for p53 showed increased bone mass. A. Normal growth plates 
in p53-/- mice. Femurs were fixed, decalcified, and stained with H&E. B. Bone mineral 
density (BMD) of the mutant and wild type mice of the same age and gender. Femur 
bones were taken from 3-4 month old p53 knockout and control mice and their bone 
densities measured (n=8, p=0.004). n is the number of mice used in the study, and p is the 
statistical analysis.  Bar in A, 500Um. Error bars represent ±SD. Asterisks mark samples 
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To further analyze the bones in p53 knockout mice, Von Kossa staining and bone 
histomorphometric analysis of the sectioned long bones were carried out. It is revealed 
that p53-/- mice had a 29% increase in the number of trabecular bones and a 40% increase 
in the volume of trabecular bones (Fig. 1C-E).  A slight increase was detected in the 
volume of cortical bones (45.7±2.8% (BV/TV) for +/+ vs. 52.4±2.7% for p53-/- of femur 


















       









        
Figure 1. Mice deficient for p53 showed increased bone mass. C. A representative Von 
Kossa staining of the femurs of mutant and control mice showing an overall improved 
trabecular bone in p53-/- mice.  D. The number of trabecular bones was increased in p53-/-  
mice (n=8, p=0.014).  E. p53-/- mice had increased trabecular bones (trabecular bone 
volume per tissue volume) (n=8, p=0.0037). 
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This phenotype of p53 knockout mice accompanied with an increase in BMD 
could be caused by either an increase in bone formation due to increased number and/or 
function of osteoblasts; or a decrease in bone resorption due to decreased number and/or 
resorptive activity of osteoclasts; or both. I then carried out calcein double labeling, a 
technique used to characterize bone formation, and a function of osteoblast 
differentiation. Mice were injected intraperitoneally with calcein in PBS twice on day 1 
and day 7 and sacrificed 2 days later and their right femurs were analyzed. In vivo calcein 
labeling revealed that p53-/- mice consistently showed a marked increase in the mineral 
apposition rate and bone formation rates at the periosteal surface (Fig. 2A-D), as well as 
in the trabecular bones (Fig. 2E-H).   
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Figure 2. Mice deficient for p53 showed increased bone formation rates. A. Calcein 
labeling of the cortical bones in mutant and control mice. Three-four month old mice 
were injected with calcein twice with an interval of 9 days. The mice were sacrificed and 
femur bones sectioned without decalcification. Pictures were taken under a fluorescence 
microscope (40X). B. Inter-label width (µm) (n=8, p=0.025). C. Mineral apposition rates 
(n=8, p=0.025). D. Cortical bone formation per bone perimeter (n=8, p=0.0004). Similar 
results were obtained for trabecular bone parameters. E. Calcein labeling of trabecular 
bones in mutant and control mice. F. Mineral apposition rates in trabecular bones (n=8, 
p=0.03). G. Trabecular bone formation rates per bone perimeter (n=8, p=0.032). H. Bone 
formation rate per bone area in trabecular bones (n=8, p=0.032). Error bars represent 
±SD. Asterisks mark samples significantly different from control with p<0.05. 
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Hence, from the above results, I were able to conclude that p53 knockout mice 
showed a disruption of normal bone remodeling. A net result is an almost 50% increase 
in both cortical and trabecular bone formation, but only a moderate increase of 
approximately 13% in BMD. The abnormal increase in BMD is reflective of an 
osteosclerotic bone disorder (Fig. 3C). From calcein kinetics studies of the p53 knockout 
mice with their wild type littermates, I hypothesize that this increase in BMD and bone 
formation in p53-/- mice could be caused by an enhanced osteoblastic activity in bone 
matrix deposition that forms bone. This could be the result of increased osteoblast 
differentiation/ function and/or increase in osteoblast number. Further analysis revealed 
to us that p53-/- mice also showed a marked increase in the osteoblast surface and the 
number of osteoblasts per bone surface (Fig. 3A & 3B). Taken together, these results 
established that p53 exerts a negative influence on either osteoblast differentiation and/or 




























                            
Figure 3. Mice deficient for p53 showed increased osteoblast number and surface.  A. 
p53-/- mice showed increased osteoblast surface (osteoblast surface/bone surface) (n=5, 
p=0.012).  B. p53-/- mice showed increased osteoblast numbers (osteoblast numbers/bone 
surface) (n=5, p=0.034).  Error bars represent ±SD. Asterisks mark samples significantly 
different from control with p<0.05. 
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3.I.2.2: p53-/- osteoblasts showed accelerated differentiation 
In an effort to decipher the cellular mechanisms leading to the increase in bone 
mass observed in p53-/- mice, I wanted first to determine whether the bone marrow 
contains the same number of osteoprogenitor cells in p53-/- mice. Total bone marrow cells 
were extracted from p53-/- mice and control littermates, counted and directly plated in a 
35mm plate. After 7 days, adherent colonies appeared on the tissue culture plate, which 
represent lineage-specific colonies and can be scored by Haematoxylin Mayer Solution. 
Those colonies stained by Alkaline phosphatase (ALP) are specific for the osteoblast 
lineage. It was found that the ALP colony forming units and total colony forming units 
were comparable between p53-/- and control mice (Fig. 4), suggesting that p53 deficiency 
did not significantly alter the differentiation potential of mesenchymal cells into 




                
Figure 4. p53 deficiency did not affect MSCs differentiation potential. A. p53 deficiency 
did not significantly alter the differentiation potential of mesenchymal cells into 
osteoblasts. Colonies containing more than 25 cells were counted (per 2.5x106 bone 
marrow cells). Left panel shows the staining picture, while the right graph shows the 
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To confirm that p53 negatively regulates osteoblast differentiation, I studied 
mutant and control calvarial osteoblasts, which formed a culture of higher purity 
compared to the bone marrow stromal culture. To compare their differentiation, the p53-/- 
and control osteoblasts were plated at 2.5 x 105/well in a 12 well plate and cultured. This 
number of cells was sufficient to cover the whole area of the culture plates and thus 
eliminated the possible effects of growth disparity on differentiation. Differentiation 
assays showed that p53-/- osteoblasts expressed more ALP (Fig. 5A), with the p53 
heterozygous culture displaying an intermediate phenotype. Quantitative assays for ALP 
(enzyme activities normalized to total protein levels or the number of osteoblasts) 
confirmed the results obtained from histological staining (Fig. 5B & 5C). During the 
second to the third week in culture, osteoblasts start to express osteocalcin (Bglap1), an 
osteoblast-specific gene that is a marker of fully differentiated osteoblasts and is involved 
in osteogenesis. Wild type osteoblasts exhibited a gradual increase in osteocalcin levels 
over time while p53-/- osteoblasts expressed maximal osteocalcin from day 0 of culture, 
suggesting that p53 negatively regulates osteocalcin expression (Fig. 5D). This is 
consistent with a report showing that p53 might directly regulate the expression of 
osteocalcin (Schwartz et al., 1999).  Similarly, increased nodule formation or bone 
mineralization was observed in p53 null osteoblast cultures (Fig. 5E) These in vitro 
results of cell cultures confirmed my in vivo results of p53-/- mice that p53 plays a role in 
osteoblast function and bone formation. It disrupts the balanced process of bone 
formation and bone resorption by inhibiting osteoblast differentiation and maturation. 
Therefore, I conclude that p53-/- osteoblasts show enhanced differentiation.  
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Figure 5. Calvarial osteoblasts from p53-/- mice showed enhanced differentiation. A.  
Calvarial osteoblasts were isolated from newborn mice and cultured to passage 3. The 
same number of cells was then plated into 12 well plates at 2.5 x 105 per well and stained 
for ALP. B.  Quantitation of ALP activities of p53-/- and control wild type cells that were 
normalized to protein levels. C. Quantitation of ALP activities of p53-/- and control wild 
type cells that were normalized to the number of cells. The ALP activity for control cells 
at day 1 was set at 1. D. Northern blot analysis shows that expression of osteocalcin 
during differentiation of p53-/- and control calvarial osteoblasts. The level of osteocalcin 
in control osteoblasts at day 0 was set at 1. E. As in A except that the cells were stained 
by Von Kossa method for mineral deposition.   
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To confirm that p53 mediated the effect on osteoblast differentiation, I introduced 
a retrovirus expressing p53 construct and vector control into osteoblastic cells and 
checked their differentiation. Reconstitution of p53 by retroviral infection blocked the 
accelerated differentiation of p53-/- osteoblasts and retroviral expression of p53 in control 
cells inhibited their differentiation (Fig. 6A & B).  These results indicate that the 
biological function of p53 in cells of the osteoblast lineage is to inhibit or slow down 
their differentiation.   
 
 
                    
 
 
Figure 6. Calvarial osteoblasts from p53-/- mice showed enhanced differentiation A & B. 
Reconstitution of p53 led to normal differentiation of p53-/- osteoblasts, justified by ALP 
staining (A) and quantitative ALP (B).  Bottom left panel of Fig. 7A shows the protein 
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3.I.2.3: p53-/- osteoblasts showed increased proliferation rates  
From the colony forming assays of MSCs, I noticed that the colonies from p53-/- 
mice are bigger in size than those in the wild type control, indicating a possibility for 
increased proliferation rate of osteoblastic cells in the absence of p53. To test whether 
p53 affects proliferation of osteoblasts, I compared the growth rates of p53-/- and control 
osteoblasts and found that in the absence of p53, osteoblasts doubled at a higher rate 
(12.0 hr for -/- vs. 19.2 hr for +/+) (Fig. 7A).  This may explain why p53-/- mice exhibit 
an increased number of osteoblasts in vivo. I also analyzed expression of proteins 
involved in cell cycle control in p53-/- osteoblasts and wild type cells. It is well-known 
that p53 plays a vital role in guarding the genome integrity of the cells by initiating cell 
cycle checkpoint control and programmed cell death. Hence, cells deficient for p53 are 
more resistant to DNA damage under genotoxic stress and may escape cell cycle arrest 
under such situations. As a result, cancer may arise. Western blot analysis revealed that 
expression of the CDK inhibitor p21was abolished in p53-/- cells and this may explain 
why p53 osteoblasts have a shortened cell cycle (Fig. 7B). Surprisingly, I found that the 
levels of p16ink4a were up-regulated, while CDK4 and cyclin D1 were down-regulated in 
p53-/- cells (Fig. 7C).  This may reflect a compensation mechanism for the loss of p53. To 
confirm that enhanced differentiation is not caused by accelerated proliferation, I 
expressed p21 in p53-/- osteoblasts with the retrovirus and found that cell proliferation 
rates were down to that of control osteoblasts (data not shown), yet these osteoblasts still 
exhibited enhanced differentiation (Fig. 7D), suggesting that enhanced differentiation 
caused by p53 deficiency is independent of cell proliferation.     
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Figure 7. Calvarial osteoblasts from p53-/- mice showed accelerated proliferation and 
enhanced differentiation. A. osteoblasts showed reduced doubling time. 4 x 105 cells 
(triplicates) were plated in 60 mm plates and the number of cells were counted every day 
for 5 days and plotted. Doubling time was calculated from three p53-/- osteoblasts and 
their control littermates. B. Expression of proteins involved in cell proliferation. The 
experiments were carried out as described in Fig. 8A and one plate was harvested each 
day for Western blot analysis. C. Quantitation data at day 3 of Fig. 8B. D. Retroviral 
expression of p21 in p53-/- osteoblasts did not significantly repress differentiation. p53-/- 
and control osteoblasts were infected with p21 expressing retrovirus (or control 
retrovirus), selected for 5 days and plated for ALP assays. Error bars represent ±SD. 
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3.I.3 p53 mediated osteoblast differentiation through osterix 
3.I.3.1: Up-regulation of osterix in p53-/- osteoblasts and mice   
To determine the molecular basis of p53 action in osteoblasts, I next asked 
whether it could influence expression or function of the known osteoblast-specific 
transcription factors such as Runx2 and Osterix. Total RNA was isolated from p53-/- and 
control osteoblasts at different stages of differentiation and used for RT-PCR assays. No 
dramatic up-regulation of Runx2 was observed during differentiation of mutant or control 
cells. Neither was there a significant difference in the basal levels of Runx2 between p53-
/- and control osteoblasts (Fig. 8A &D). These data suggest that the effect of p53 on 
differentiation is not mediated by Runx2. On the other hand, p53-/- osteoblasts showed a 
significant elevation of osterix at the basal level (Fig. 8A). In both p53-/- and control 
osteoblasts, expression of osterix peaked rapidly at day 2 and subsided to basal levels 
later on.  Still, p53-/- osteoblasts displayed a much higher peak value than control cells, 
suggesting that p53 may function to suppress the expression level of osterix. Quantitative 
assays of osterix mRNA by real time PCR revealed an average of a 13 fold increase in 
osterix mRNA levels in p53-/- osteoblasts at the basal level (Fig.8B). More interestingly, 
western blot analysis of the p53 protein expression at the same stages of osteoblast 
differentiation revealed a reverse correlation between the p53 levels and the osterix 
mRNA levels. I found that expression of p53 was minimal from day 1 to day 2 but was 
dramatically up-regulated at day 4 during differentiation, a time point when osterix 
expression was minimal, indicating the possible negative correlation of p53 with osterix 
(Fig. 8C). However, the up-regulation of osterix in cells deficient for p53 could not be 
explained and I suspect that this up-regulation of osterix could be a cell response to bone 
morphogenetic proteins (BMPs) that are secreted by osteoblasts. What causes this 
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increase in p53 levels is not clear. The results suggest that elevated expression of p53 
may contribute to the down-regulation of osterix at later stages of osteoblast 
differentiation and that the effect of p53 on osteoblast differentiation is downstream of 
Runx2 and upstream of osterix and the significance of p53 regulation warrants further 
investigation.   
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Figure 8. Osteoblasts deficient for p53 showed up-regulated expression of osterix but not 
Runx2. A. Mutant and control osteoblasts were collected at different stages of 
differentiation. Total RNA was isolated and used for RT-PCR. B. Total RNA was 
isolated from p53-/- and control osteoblasts and used for real time PCR. C. Expression of 
p53 changed during osteoblast differentiation.  Cells at different stages of differentiation 
were harvested and the levels of p53 were determined by Western blot analysis. D. 
Quantitation data from A and C (similar results were obtained from 4 pairs of p53-/- and 
control osteoblasts). The level of osterix, Runx2, or p53 in control osteoblast was set at 1. 
Asterisks mark samples significantly different from control with p<0.05. 
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To demonstrate that osterix is elevated in vivo, I isolated total RNA from the 
calvaria of p53-/- and control littermates and performed RT-PCR experiments. RNA was 
directly obtained from the homogenization of calvaria of 20 day old embryos from p53-/- 
mice and their control littermates and analyzed for RT-PCR expression. I found that 
osterix, but not other transcription factors such as Runx2 or Dlx5, was up-regulated in 
calvarial bones of p53-/- mice compared to control mice (Fig. 9A & B).  Similar to the in 
vitro results, Real-time PCR assays detected an almost 15 fold increase in the level of 
osterix mRNA in calvaria of p53-/- mice while no significant alteration was observed in 
the levels of Runx2 and Dlx5. In situ hybridization using RNA probes generated from the 
osterix coding sequence confirmed the results (Fig. 9C).  From the microscopic picture, 
Osterix was found to be mainly expressed at sites of mature osteoblasts beneath the 
growth plates.  Overall, these results suggest that one function of p53 is to inhibit osterix 
expression and hence osteoblast differentiation.  Since overexpression of osterix in non-
osteoblastic cells such as C2C12 and C3H10T1/2 promotes their differentiation to 
osteoblasts (Nakashima et al., 2002), I speculate that elevated levels of osterix in p53 
deficient osteoblasts may account for the bone related osteosclerotic phenotypes of the 
knockout mice.            
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Figure 9. Osteoblasts deficient for p53 showed up-regulated expression of osterix but not 
Runx2. A & B. Elevated expression of osterix mRNA was observed in calvaria of p53-/- 
mice. Total RNA was made from calvaria of  p53-/- and control mice and then used for 
RT-PCR for osterix, Runx2, and Dlx5 (A) or real time PCR for osterix (B) to assess the 
mRNA levels of osterix. The level of osterix mRNA in control calvaria was set at 1.  The 
internal control for real time PCR was GAPDH mRNA. C. In situ staining of osterix 
mRNA. Femurs of p53-/- and control mice were OCT-embedded and cryo-sectioned, 
fixed, and then hybridized with radio-labeled osterix anti-sense RNA probe. Bar in A, 
500Um. Error bars represent ±SD. Asterisks mark samples significantly different from 
control with p<0.05.  
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3.I.3.2: p53 repressed the promoter activity of osterix 
Two experiments further support the notion that p53 plays a negative role in 
osterix expression. Primary mouse embryonic fibroblasts (MEFs) were used. The 
advantage of MEFs is that they do not express osterix and cannot spontaneously 
differentiate into osteoblasts; yet they do start to express osteoblasts-specific markers like 
ALP upon BMP stimulation. I stimulated p53-/- and control MEFs with BMP2 for 
different periods of time. RT-PCR assays revealed that control MEFs showed minimal 
induction of osterix, while p53-/- MEFs showed substantial induction of osterix. I found 
that osterix was markedly induced in p53-/- MEFs compared to control cells, in response 
to a short-term treatment with BMP2 (Fig. 10A).  Furthermore, under conditions when 
p53 was up-regulated, for example by DNA damage reagent cisplatin, the expression of 
osterix was repressed in wild type primary osteoblasts, but not in p53-/- osteoblasts, 
suggesting that an increase of p53 could further repress osterix expression (Fig. 10B).  
These in vivo results confirmed that p53 is a negative regulator of osterix.  



































Figure 10. p53 mediated the accelerated differentiation of  osteoblasts. A. Induction of 
osterix mRNA by BMP2 in and control MEFs. MEFs were stimulated with 100ng/ml of 
BMP2 for different periods of time. Total RNA was isolated and RT-PCR was 
performed. Similar results were obtained from three pairs of mutant and control MEFs.  
The level of osterix in control cells at time 0 was set at 1. B. DNA damage inhibited the 
expression of osterix. p53-/- and control osteoblasts were treated with 5 µM or 10 µM of 
cisplatin for 24 hours and total RNA was isolated for RT-PCR assays. The values of Y 
axis were normalized to the level of actin, with the basal level of control cells set at 1 
(lower panel). Upper panel: Western blot analysis of p53 induction by cisplatin in control 
osteoblasts.  * p<0.05 compared to the same genotype without CDDP treatment.  
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To test whether p53 represses the transcription of osterix, a 6.0 kb DNA fragment 
upstream of the transcription start site of osterix gene (Osx) was fused to the luciferase 
gene in pGL3 basic vector. The osterix promoter showed at least 6 fold induction 
compared to the luciferase activity of the basic vector (Fig. 11A). Co-expression of p53 
led to a dosage dependent repression of Osx promoter activity in C2C12 and MC3T3-E1 
cells (Fig. 11B). Two cell lines are tested in luciferase assays: The mouse calvaria-
derived cell line MC3T3-E1 and the C2C12 cell line. MC3T3-E1 expresses osteoblast 
markers ALP and osteocalcin mRNA. It also forms the mineralized extracellular matrix, 
but only upon addition of L-ascorbic acid in culture. C2C12 is a mouse progenitor cell 
line that could be induced to become osteoblastic by BMP-2 and starts to express ALP.  
 
 




























Figure 11. p53 inhibited the promoter activity of osterix.  A Osterix promoter was cloned 
into PGL3 Basic Vector and transfected into C2C12 and MC3T3-E1 cells and the 
luciferase activity measured B. Co-expression of p53 inhibited the basal level of the 
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I then went on to test the repression of the osterix promoter with various p53 
mutant constructs. p53R273H, a mutant with no DNA binding ability, still significantly 
repressed Osx promoter (Fig. 12A), suggesting that DNA binding may not be absolutely 
required.  Moreover, p53S15A, a mutation of a phosphorylation site important for 
transactivation of p53 target genes in response to DNA damage, could repress Osx 
promoter. On the other hand, p53 mutants such as p53Δ62-91 (the proline rich domain 
deleted), p53M246I (point mutation in the DNA binding domain) and p53L22Q/W23S 
(two point mutations that abolish p53 transactivation activity), which were reported to 
have non- or dramatically reduced ability in repressing other p53 target genes (Roth et 
al., 2000; Murphy et al., 1996; Venot et al., 1998), failed to repress Osx promoter (Fig. 
12A). These results suggest that p53 might repress Osx promoter activity with a common 
mechanism as in repression of Cdc25C and Cdc2 (Karen Van Orden, et al., 1999; Carol 
Imbriano, et al., 2005). The fact that some mutant p53 molecules, except Ser15A and 
R273H (partially), failed to repress the promoter activity, suggesting that the R273H and 
M246I mutations, both in the DNA-binding domain of p53, might affect other p53 
functions in addition to DNA-binding. A similar case has been reported (Mirza et al., 
2002). 
The following observations further confirmed that p53 represses Osx promoter 
independent of DNA binding.  First, no canonical p53 binding site was present in the 6 kb 
promoter sequence. Although there are two suspected sites in the first 1.5 kb promoter, 
they are not perfect and found to be not important in p53-mediated repression from 
mutation experiments. Secondly, serial deletion experiments indicated that all fragments 
(6, 4, 2, 1.0, 0.5, 0.3, and 0.13 kb upstream of the start site) could still be repressed by 
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p53 (Fig. 12B).  This 0.13 kb fragment contains mainly the TATA box like sequence with 
no typical p53 binding motifs and is a minimal sequence that still retains some activity in 
a reporter assay. Thirdly, chromatin immunoprecipitation (ChIP) assays demonstrated 
that p53 was not directly associated with the 2 kb sequence of the osterix promoter even 
though its binding was detectable at the p21 promoter (Fig. 12C). Eletromobility shift 
assay (EMSA) confirmed that there is no binding of p53 to a 2kb osterix promoter. These 
results suggest that p53 repressed osterix transcription independently of its binding to the 
upstream activation sequence or specific binding sites.   
I also found that p300, among several transcription factors and coactivators, could 
activate Osx promoter, and this activation was repressed by p53 as well (Fig. 12D).  Since 
p300 is expressed in the cells at a limiting concentration, it is possible that p53 might 
squelch this co-activator to repress gene transcription, as proposed previously (Vo and 
Goodman, 2001; Soussi and Lozano, 2005). To date, p53 has been reported to inhibit the 
transcription of many genes like Osx. Yet the molecular mechanisms behind the 
repression are not well understood.  This prevents us from establishing the exact role for 
p53 in repression of Osx transcription.   
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Figure 12. p53 inhibited the promoter activity of osterix. A. Effects of p53 mutants on 
the osterix promoter activity. Each of these p53 mutant constructs was co-transfected into 
C2C12 cells with the reporter gene and their luciferase activity was measured. B. Serial 
deletion analysis of the osterix promoter. Different constructs were co-transfected into 
C2C12 cells with 1x p53 expression construct and the luciferase activities were measured 
as in Fig. 14A. The repression was compared to the 6 kb promoter (+++). C Chromatin 
immunoprecipitation assays (ChIP) indicates that p53 does not bind directly to the 2 kb 
promoter of Osx. p21 promoter was used as a positive control. D. p53 repressed Osx 
promoter activity in the presence of p300. The experiments were carried out the same as 
in Fig. 14 A except that TBP or p300 was included.  
Osterix promoter  
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3.I.3.3: Elevated osterix mediated enhanced differentiation of p53-/- 
osteoblasts 
I then attempted to determine whether elevation in osterix mediated the enhanced 
differentiation of p53-/- osteoblasts. Osterix antibody was generated by injecting a 
designed peptide into rabbits. Retroviral osterix construct was also established for osterix 
over-expression in cells. Osterix corresponds to a protein size of approximately 44 kDa. I 
first tested whether osterix overexpression could lead to enhanced differentiation. p53-/- 
and control osteoblasts were infected with retroviruses expressing osterix, selected 
against puromycin for 3 days, and then used for ALP or osteocalcin assay (Fig. 13A-E).  I 
observed a retroviral dose dependent increase in osterix levels (Fig. 13C &D), likely due 
to multiple infections in a single cell.  An up-regulation in ALP activities and osteocalcin 
was also seen (Fig. 13A, B &E).  When retrovirus-infected wild type osteoblasts 
expressed osterix to the level of p53-/- osteoblasts, they expressed similar levels of ALP 
and osteocalcin as p53-/- cells (Fig. 13B & E).  These results indicate that elevation of 
osterix could promote osteoblast differentiation and the enhanced differentiation of p53-/- 
osteoblasts might be at least partially mediated by the increased expression of osterix. 
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Figure 13. Elevated expression of osterix was necessary and sufficient for accelerated 
differentiation of osteoblasts. A. Ectopic expression of osterix led to increased expression 
of osteoblast markers ALP.  Wild type primary osteoblasts were infected with increasing 
amounts of retrovirus expressing osterix, selected for 3 days, and then stained for ALP.  
B. Western blot analysis showed the levels of osterix in cells infected with the retrovirus 
(upper panel).  RT-PCR assays showed the increase of osteoblast marker osteocalcin in 
response to ectopic expression of osterix (lower panel). C. ALP activities normalized to 
the level of proteins. Control cells infected with vector was set at 1.  D. Quantitation data 
for the protein levels of osterix of Fig. 15B.  Control cells infected with vector were set at 
1. E. Quantitation data for the mRNA levels of osteocalcin of Fig. 15B. Control cells 
infected with vector was set at 1.   
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Secondly, I attempted to determine whether increased osterix expression was 
required for the enhanced differentiation of p53-/- osteoblasts. In order to demonstrate that 
elevated levels of osterix accounted for enhanced differentiation of p53-/- osteoblasts, I 
decided to knock down osterix in p53-/- osteoblasts and test whether this affects 
differentiation using siRNA oligos. siRNA mediated knocking down of osterix was 
carried out in control and p53-/- osteoblasts and osteoblast differentiation markers were 
analyzed (Fig. 14A-E).  Different combinations of siRNA species reduced osterix to 
different levels (Fig. 14C & D), leading to decreased expression of ALP and osteocalcin 
(Fig. 14A, B, C and E).  The results suggested that osterix was necessary for osteoblast 
differentiation and that the effect of p53 on osteoblast differentiation might be at least 
partially mediated by osterix.   
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Figure 14. Elevated expression of osterix was necessary and sufficient for accelerated 
differentiation of osteoblasts. A. Knocking down of osterix (a1 to a5) led to a reduction in 
ALP expression in osteoblasts. p53-/- and control osteoblasts were transfected with 
siRNA against osterix and control oligos for 2 days and the plates were stained for ALP.  
Different combinations of 4 commercially designed siRNA species were used to obtain 
different degrees of knocking down.  a1, 1+2 siRNA duplexes; a2, 3+4 duplexes; a3, 1-4 
duplexes; a4, 1-4 duplexes (2x); a5, 1-4 duplexes (4x).  B. Western blot analysis showed 
the levels of osterix in cells transfected with siRNAs (upper panel). RT-PCR assays 
showed the decrease of osteoblast marker osteocalcin in response to knocking down of 
osterix (lower panel). C. ALP activities normalized to the level of proteins. Control cells 
transfected with control siRNAs was set at 1. D. Quantitation data for the protein levels 
of osterix of Fig. 16B. Control cells transfected with control siRNAs was set at 1. E. 
Quantitation data for the mRNA levels of osteocalcin of Fig. 16B. Control cells 
transfected with control siRNAs were set at 1.   
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3.I.4 Events of coupling and signaling for p53 regulated osteoblasts 
3.I.4.1: p53-/- osteoclasts showed normal differentiation and resorption 
in culture 
Increased bone mass could be attributed to reduced bone resorption in addition to 
increased bone formation. Further analysis of the mice femur with histomorphometry 
revealed an unanticipated result.  p53-/- mice showed a one fold increase in the bone 
resorption surface and the number of osteoclasts (Fig. 15A and B). To study the 
osteoclastic resorptive activity in vivo, the morning urine of the mice was collected from 
mice manually. Pyridinium stabilizes the extracellular matrix in bone and cartilage by 
creating covalent bonds between adjacent collagen chains. This substance could be 
broken down by osteoclasts, generating a product called deoxypyridinoline (DPD) 
crosslinks that are released into the circulation and excreted in urine. It is therefore 
reflective to the bone resorption activity in vivo. This DPD crosslinks values could be 
measured and normalized to control urine creatinine values to give a fair evaluation of 
bone resorption rates in mice. p53-/- mice showed an increase in excretion of urine 
deoxypyridinoline (DPD) crosslinks (Fig. 15C).  These data indicate that p53-/- mice have 
increased bone resorption in vivo in addition to increased bone formation. This may 
explain why p53-/- mice only showed modest osteosclerotic phenotypes with a slight 
increase in bone mass despite bone formation rates of both cancellous and cortical bones 
being nearly double of that of control mice.   
To determine whether deficiency of p53 has a cell autonomous effect on 
osteoclasts, I analyzed osteoclastogenesis and osteoclast resorption of p53-/- and control 
bone marrow monocytes (BMMs) in vitro in the presence of M-CSF and RANKL, which 
are necessary and sufficient for osteoclast proliferation and differentiation. No significant 
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difference was observed in the number of osteoclasts formed from p53-/- and control 
BMMs (Fig. 15D &E). Nor did I observe a significant difference in the bone resorption 
activities of the p53-/- and control osteoclast cultures based on pit formation on dentine 
slices. These slices are used for mature osteoclasts to resorb on and are often used to test 
the osteoclastic resorptive activity in vitro (Fig. 15F&G). These results suggest that p53 




























Figure 15. Effects of p53 deficiency on osteoclast differentiation and resorption. A. p53-/- 
mice showed increased osteoclast surface (osteoclast surface/bone surface) (n=8, 
p=0.013). B. p53-/- mice showed an increase in the number of osteoclasts per bone surface 
(n=8, p=0.002). C. Urinary deoxypyridinoline (DPD) cross-links excretion was 

























































Figure 15. Effects of p53 deficiency on osteoclast differentiation and resorption. D. 
Normal osteoclast differentiation from bone marrow monocytes in p53-/- mice in presence 
of M-CSF and RANKL. E. Quantitation data from five p53-/- and control littermate mice. 
F. Normal bone resorption rates of p53-/- osteoclasts. Pit formation assays of p53-/- and 
control osteoclasts (two representative views of different magnifications, left: stained 
with Toluidine blue; right: stained with Gill's Haematoxylin Solution). G. Quantitation of 
the resorption area and control osteoblasts (n=4).  
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3.I.4.2: p53-/- osteoblasts had increased osteoclastogenic capabilities 
secondary to an increase in M-CSF  
The findings described above raised the possibility that increased activities of 
p53-/- osteoblasts led to increased osteoclastogenesis and bone resorption in vivo.  It has 
been well established that osteoblasts control osteoclast differentiation by synthesizing 
M-CSF, RANKL, and OPG (Boyle et al., 2003; Suda et al., 1999).   
To prove this, I co-cultured primary calvarial osteoblasts (p53-/- or control) with 
BMMs (p53-/- or control) in the presence of 10-8 M dihydroxyvitamin D3, and then 
stained for TRAP positive cells (Fig. 16A & B).  Primary osteoblasts were plated at a 
high density so that the plates would become confluent overnight. This is to eliminate any 
possible effects of growth disparity of osteoblasts on osteoclast differentiation. These 
TRAP positive osteoclasts were much smaller compared to those formed in the presence 
of M-CSF and RANKL (Fig. 16D), with a small portion being multinucleated, similar to 
what has been observed in previous studies (Geoffroy et al., 2002).  Nevertheless, p53-/- 
osteoblasts exhibited a marked increase in the number of TRAP positive osteoclasts 
regardless of the genotype of BMMs, compared to p53+/+ osteoblasts. When only cells 
with ≥3 nuclei were counted, a 2.5 fold increase was observed for monocytes (both 
p53+/+ and p53-/-) cultured on p53-/- osteoblasts compared to those cultured on control 
osteoblasts (Fig. 16C).  p53-/- and p53+/+ monocytes behaved similarly when cultured on 
p53-/- osteoblasts or wild type osteoblasts, confirming that p53 did not have a cell 
autonomous effect on osteoclastogenesis (Fig. 16D & E). These results indicated that 
osteoblasts deficient for p53 had increased potentials in promoting osteoclastogenesis and 
that the increased osteoclast number and bone resorption observed in p53-/- mice might be 
attributable to the enhanced activities of p53-/- osteoblasts. In accordance with the 
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enhanced osteoclastogenesis, RT-PCR analysis revealed a significant increase in the level 
of M-CSF in p53-/- osteoblasts, but not that of RANKL or OPG (Fig. 16D). M-CSF 
controls both the proliferation and the differentiation of osteoclasts (Tanaka et al., 1993; 
Sarma and Flanagan, 1996). Moreover, ectopic expression of osterix in primary cells was 
found to increase the level of M-CSF in a dosage-dependent manner, suggesting that the 
enhanced osteoclastogenic capacity of p53-/- osteoblasts could be attributed to elevated 
expression of osterix (Fig. 16E).  
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Figure 16. p53-/- osteoblasts show greater osteoclastogenesis capacity. A. p53-/- 
osteoblasts showed a much greater stimulatory effect on osteoclastogenesis. p53-/- and 
control osteoblasts were first plated and then the bone marrow monocytes isolated from 
p53-/-  and control mice were plated.  They were co-cultured for 6 days in the presence of 
10-8 M of vitamin D3 and then stained for TRAP positive osteoclasts.  B. Quantitation 
data from H (n=4).  
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Figure 16. p53-/- osteoblasts show greater osteoclastogenesis capacity. C. Number of 
TRAP positive cells/well with ≥3 nuclei. * p<0.05 comparison between 
osteoclastogenesis (+/+ or -/- monocytes) on +/+ osteoblasts and on -/- osteoblasts. D. 
Up-regulation of M-CSF in p53-/- osteoblasts.  RT-PCR analysis of the mRNA levels of 
M-CSF in p53-/- and control osteoblasts.  The levels of M-CSF mRNA for control cells 
were set at 1. E. Ectopic expression of osterix increased the expression of M-CSF.   
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3.I.5 p53 acts  downstream of c-Abl in osteoblast differentiation 
I first tried to generate double knockout mice for c-Abl and p53 and analyze their 
bone phenotypes. Unfortunately, compound homozygous mice for c-Abl and p53 were 
very difficult to obtain, probably owing to the embryonic and/or postnatal lethality of 
these mice. Nevertheless, I isolated calvarial osteoblasts from four 20 day embryos of 
double homozygous mice and control littermates, and compared their differentiation 
potential.  The compound knockout cells behaved similarly to p53-/- osteoblasts in ALP 
expression and in mineral deposition (Fig. 17A, B&C). Real time PCR assays indicated 
that osterix expression was down-regulated in c-Abl deficient cells but up-regulated in the 
compound double knockout mice, resembling p53-/- osteoblasts (Fig. 17D). These data 
suggest that p53 functions downstream of c-Abl in the process of osteoblast 
differentiation and in bone development.  
 























    














                                                                             
                                           










Figure 17. Osteoblasts deficient for both p53 and c-Abl showed advanced differentiation.   
Compound knockout and control osteoblasts were isolated from 2 litters, plated and 
stained for ALP (A), quantitative ALP (B), Von Kossa (C), and for assessment of osterix 
mRNA levels (D). The bottom panel shows the osterix mRNA, while the upper graph 
shows the quantitation data for day 4 together with single homozygous mice. Error bars 
represent ±SD. Asterisks mark samples significantly different from control with p<0.05. 
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Chapter 4: Conclusion and Discussion 
to Result Part I 
4.1: a novel role for p53 in bone remodeling 
I provide genetic evidence that p53 plays a negative role in postnatal bone 
development with a cell-autonomous effect on osteoblastogenesis.  The mice deficient for 
p53 displayed increased bone formation and osteosclerotic phenotypes; the osteoblasts 
deficient for p53 showed enhanced proliferation and accelerated differentiation; and p53 
deficiency could overcome the differentiation defects of c-Abl-/- osteoblasts. Moreover, 
p53 deficiency confers the osteoblasts a greater osteoclastogenic capacity, without 
directly affecting osteoclast differentiation or resorption. Accordingly, increased bone 
resorption was also observed in p53-/- mice. Thus the osteosclerotic phenotype is a net 
result of the direct effect of p53 on osteoblast action combined with an osteoblast-
mediated effect on osteoclasts. This osteoblast-supported osteoclastogenesis might 
explain why most of the osteosclerosis models associated with enhanced osteoblast 
function do not exhibit a huge increase in bone mass (Ducy et al., 2000; Ducy et al., 
1996) (and discussed in (Sabatakos et al., 2000; Manolagas and Jilka, 1995)).   
This conclusion that p53 plays a negative role in osteoblastogenesis is supported 
by the findings that p53 might directly regulate the expression of osteocalcin (Chandar et 
al., 2000).  However, my results are not in agreement with a recent report stating that p53 
did not affect osteoblast differentiation and mouse bone formation, although they did 
show that p53 deficiency rescued the bone loss induced by mechanical unloading (Sakai 
et al., 2002). The discrepancy could be caused by the genetic background (C57BL/6 in 
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my studies, not mentioned in the other report), or the age of the mice used (4 months in 
my studies vs. 2 months), and warrants further investigation. Nevertheless, my results 
obtained from studies on whole mice, the bones, the cells involved, and the participating 
molecules convincingly support a negative role for p53 in osteoblastogenesis and bone 
formation, which contributes to the osteosclerotic phenotype observed in p53-/- mice. I 
also provided genetic evidence to support that p53 functionally acts downstream of c-Abl 
in postnatal bone development.   
My findings indicate that p53 plays a role in osteoblast differentiation without 
directly affecting the differentiation of osteoclasts in a cell-autonomous manner. The 
significance of the link between p53 and bone development is underscored by the recent 
findings that p53 cooperates with TGF-β/BMP pathways to positively regulate early 
development of Xenopus (Cordenonsi et al., 2003; Takebayashi-Suzuki et al., 2003), 
which is in contrast to the negative role for p53 in bone homeostasis. One explanation for 
the opposite roles of p53 in relationship to the TGF-β/BMP pathways could be the timing 
of these two events.  Mesoderm differentiation occurs at an early stage when p53 levels 
are high, while osteoblast differentiation occurs at a much later stage when p53 levels 
start to decline (Almog and Rotter, 1997). The inhibition of osterix by p53 may provide a 
mechanism to block bone development in early embryos.   
4.2: p53 negatively regulates osterix 
Several lines of experiments suggest that p53 inhibits osteoblast differentiation as 
a result of repressing the expression of a lineage specific transcription factor osterix.  
First, the in vivo and in vitro data indicate that osterix, but not other tested transcription 
factors, was elevated in the absence of p53.  Secondly, when p53 was up-regulated, 
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osterix expression was repressed and osteoblast differentiation was impeded. Thirdly, 
BMP2-induced osterix expression was enhanced in the absence of p53. Fourthly, p53-/- 
osteoblast differentiation could not be effectively repressed by c-Abl deficiency, 
consistent with sustained expression of osterix under this condition. Moreover, p53 was 
found to inhibit the promoter activity of osterix while some mutant forms of p53 failed to 
do so.  Lastly, I found that the osterix levels are an important determinant in osteoblast 
differentiation, as overexpression of osterix led to enhanced differentiation and knocking 
down of osterix led to reduced differentiation in p53 deficient osteoblasts.  My findings 
might provide the first example in which p53 mediated gene repression has a 
physiological impact on postnatal mouse development. My results suggest that p53 might 
do so by inhibiting osterix promoter activity by the minimal promoter independently of 
its binding to the upstream activation sequence.  There is an increasing number of genes 
that are controlled by the core promoter sequence including the TATA box (minimal 
promoter) and it is also becoming evident that general transcription factors such as TBP 
and TAFs, which are associated to the core promoter sequences, can selectively regulate 
the transcription of certain genes (Hochheimer and Tjian, 2003; Green, 2000).  Moreover, 
p53 also forms a complex with p300/CBP, which interacts with the basal transcription 
machinery (Vo and Goddman, 2001). My results suggest that p53 might repress Osx 
expression by squelching p300. Still how p53 regulates transcription of Osx warrants 
further investigation.   
In July 2005, a report stated that the nuclear factor of activated T cells (NFAT) 
and osterix could form a complex that binds to DNA. Together they synergistically 
regulate osteoblastic bone formation. Similar to my findings, there is also a coupled 
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osteoclast differentiation. When there is an inhibition of NFAT proteins, both processes 
of bone formation and bone resorption are impaired due to defective differentiation of 
osteoblasts and osteoclasts respectively. It remains to be seen whether p53 could play a 
role in the transcriptional activity of osterix in cooperation with NFAT.  
My findings also indicate that p53 has a cell-autonomous role in osteoblast 
differentiation and proliferation.  It is also reported that Li-Fraumeni syndrome patients 
develop osteosarcoma as a component tumour and that p53 is mutated in 24% to 42% of 
osteosarcoma (Varley et al., 2003; Toguchida et al., 1992).  Osteosarcoma, a type of bone 
cancer is usually developed from osteoblasts and is related to periods in life with rapid 
bone growth.  These observations suggest that p53 plays an important function in bone 
growth.  More interestingly, osterix has been implicated in osteosarcoma development, as 
osterix is down-regulated in both human and mouse osteosarcoma cell lines and 
transfection of osterix into osteosarcoma cells inhibits their growth (Cao et al., 2005b).  It 
will be interesting to determine whether down-regulation of osterix is related to the p53 
status in osteosarcoma cells, and whether osterix could control p53 in a feedback loop in 
development of bone cancer.  In many tumour cell lines, p53 is mutated but its expression 
is greatly up-regulated. Dependent on the nature of the mutations, up-regulated p53 may 
repress osterix expression. For example, a hot spot mutation R273H, can still repress 
osterix promoter activity.      
4.3: Coupling between osteoblasts and osteoclasts 
Osterix is a Sp1-like transcription factor that has been studied in early 
development of mouse. It is essential for osteoblast maturation. Osterix has three Zinc-
finger domains and is able to bind to consensus Sp1-binding site (Nakashima et al., 
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2002). Here I show that p53 deficiency results in elevation of osterix and enhanced 
osteoblastogenesis.  Cell culture studies confirmed that osterix is sufficient and necessary 
for osteoblast differentiation. My results also suggest that osterix regulates the expression 
of M-CSF to control osteoclastogenesis.  M-CSF actually contains in its promoter a Sp1-
binding site, which mediates the effects of estrogen on M-CSF expression and 
osteoclastogenesis (Srivastava et al., 1999).  It is likely that osterix directly controls M-
CSF expression. The fact that M-CSF could be synthesized as a soluble, matrix or 
membrane bound growth factor may allow the molecule to circulate and probably act 
locally to control migration, differentiation and survival of osteoclastic cells in the 
mononuclear phagocytic lineage. Exactly, how osterix could control M-CSF remains a 
question to be answered. It may allow us to comprehend coupling factors regulating the 
two processes of osteoblastic bone formation and osteoclastic bone resorption in the 
maintenance of a constant, homeostatically controlled bone skeleton. Recent studies 
revealed that transcription factors involved in osteoblast differentiation also regulate 
osteoclast differentiation through controlling RANKL and OPG expression. In 
differentiated osteoblasts, the Wnt pathway and TCF1/4 were found to regulate the 
expression of osteoprotegerin and osteoclast differentiation (Glass et al., 2005).  ATF4, a 
CREB-related transcription factor that is essential for osteoblast differentiation and 
function, also regulates the expression of RANKL and subsequently osteoclast 
differentiation (Glass et al., 2005).       
In summary, p53 deficient mice show an osteosclerotic phenotype, which is a net 
result of increased bone formation and increased bone resorption. p53 deficient 
osteoblasts exhibit accelerated proliferation, enhanced differentiation, and increased 
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osteoclastogenic activities. Enhanced differentiation can be mediated by an elevation of 
osterix expression and improved osteoclastogenesis can be mediated by an increased 
expression of M-CSF, which is also induced by elevated osterix. These findings suggest 
that p53 might control bone remodeling by modulating expression of osteoblast specific 
transcription factor osterix (Illustration 7). Hence, I show that p53 functions as a negative 
regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis and bone 
remodeling.   
      














Illustration 7: A simplified model depicting my research findings. OB: Osteoblast, OC: 
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Chapter 5: Results to Part II 
5.II.1 Rationale and objectives of research to Part II 
The role of c-Abl in DNA damage remains elusive and controversial after its 
identification in the early eighties (Van Etten, 2003). The current view is that c-Abl is 
activated by DSBs in an ATM dependent manner and it stabilizes p53/p73 to promote 
apoptosis.  
The inconsistency on functions of c-Abl might arise from utilization of 
immortalized cell lines. It is now known that cells experience activated DNA damage 
response before turning cancerous, which selects cells with defective DNA damage 
response. To elucidate the physiological role of c-Abl, I used primary mouse embryonic 
fibroblasts (MEFs) at early passages.  
To investigate a detailed pathway involving c-Abl in genotoxic stress response, 
various agents were used to induce DNA damage. Namely the damage was induced by IR 
and drugs such as Adriamycin (AD), Hydroxyurea (HU), Cisplatin (CDDP) and 
Aphidicolin (APH). The scope of the research also includes a comprehensive 
examination of the downstream events of cell cycle checkpoint, DNA repair and 
apoptosis involving ATM/ATR, Chk1/Chk2, p53 and cell cycle regulators such as p21, 
14-3-3 in the absence of c-Abl.  
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5.II.2 involvement of c-Abl in nuclear foci 
5.II.2.1: c-Abl-/- MEFs showed altered nuclear foci assembly of TopBP1, 
Brca1, 53BP1 and Rad51 
One of the early responses to DNA damage is the assembly of proteins including 
sensors, transducers, and effectors at DSBs or ssDNA, forming nuclear foci that serve as 
centers for cell signaling and DNA repair. To test whether c-Abl has a role in this cellular 
event, c-Abl-/- and control MEFs were treated with adriamycin for different periods of 
time and then immuno-stained for endogenous TopBP1, a foci protein that contains 
BRCT motifs and interacts with c-Abl (Zeng et al., 2005). Untreated MEFs showed no 
foci formation and TopBP1 was evenly distributed in the nucleus. The nucleus is 
uniformly stained, sometimes with a hole that is likely to be the nucleolus (Fig. 18). 
However, under treatment with 1µM of adriamycin, the nucleus showed small dots. 
Notably the nucleolus is no longer visible. After two hours of adriamycin treatment, wild 
type and c-Abl-/- MEFs started to form foci with more c-Abl-/- cells being foci positive.  
Moreover, c-Abl-/- MEFs displayed an increased number of foci compared to that of WT 
cells at 8 or 16 hr after adriamycin treatment.  After 24 hrs of treatment, wild type cells 
started to lose foci while c-Abl-/- MEFs retained a significant number of foci (Fig. 18A 
&E).  Normal levels of nuclear foci formation were observed upon retroviral 
reconstitution of c-Abl in c-Abl-/- MEFs (Fig. 18A&E).  These results suggest that c-Abl 
plays a role in TopBP1 assembly onto nuclear foci even though c-Abl itself is not 
localized there. This is consistent with the observation that c-Abl dissociates from 
TopBP1 after DNA damage.   
I also tested whether c-Abl deficiency affects foci assembly of several other 
proteins. Brca1, a tumour suppressor involved in DNA damage signaling and DNA 
                                                                                              Chapter 5-Results to Part II 
 121
repair, colocalizes with TopBP1 on nuclear foci (Foray et al., 2002). I found that c-Abl-/- 
MEFs showed an increased number of Brca1 foci, and more c-Abl-/- cells were positive 
for Brca1 foci (Fig. 18B&E).  Similar results were observed for 53BP1, a foci protein that 
interacts with TopBP1 (Yamane et al., 2002), and for Rad51, a c-Abl interacting protein 
that is involved in HRR of DSBs (Yuan et al., 1998) (Fig. 18C, D & E). These results 
suggest that c-Abl plays a relatively general role in controlling DNA damage induced 
nuclear foci formation.  

































































Figure 18. c-Abl-/- MEFs showed altered nuclear foci assembly of TopBP1, Brca1, 
53BP1, and Rad51.  (A) c-Abl-/-, c-Abl reconstituted c-Abl-/-and control MEFs were 
treated with adriamycin for different periods of time or different dosages and then 
immuno-stained for endogenous TopBP1. Lower  panels showed quantitation data from 
A. 
 












































Figure 18. c-Abl-/- MEFs showed altered nuclear foci assembly of TopBP1, Brca1, 
53BP1, and Rad51. c-Abl-/-, c-Abl reconstituted c-Abl-/-and control MEFs were treated 
with adriamycin for different periods of time or different dosages and then immuno-
stained for endogenous Brca1 (B), 53BP1 (C), and Rad51 (D). Panel B, C and D are 
treated with adriamycin for 8hours. E. Quantitation data from B-D. Foci forming cells 
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5.II.2.2: c-Abl does not alter foci formation of H2AX, Mre11, Atm, or 
Atr  
MRN and Atm are among the early proteins assembled at the foci. I then looked 
at the foci formation for Mre11 following adriamycin treatment and found that c-Abl 
deficiency did not significantly affect the foci assembly of Mre11 (Fig. 19A). Since MRN 
is assembled at DSBs as a complex (Petrini et al., 1999), I believe that c-Abl may not be 
involved in proper assembly of MRN to the foci. This is also in agreement with the 
findings that Mre11 and Rad51 are not co-localized on nuclear foci (Maser et al., 1997).  
Similarly, c-Abl deficiency showed no effect on the foci formation of Atm or phospho-
Atm (S1981) (Fig. 19B &C), indicating that c-Abl may not be required for the assembly 
of Atm onto the foci in response to adriamycin induced DSBs. I then tested foci 
formation for γH2AX, a histone 2A variant that is the target of Atm and Atr.  Both c-Abl-
/- and control MEFs showed similar numbers of foci in response to 1 µM of adriamycin 
treatment for 8 and 16 hour (Fig. 19D), or 10 µM of adriamycin for 8 hours (bigger foci). 
These data suggest that c-Abl does not affect phosphorylation of H2AX at the foci.  Since 
the number of H2AX foci correlates with the number of DSBs (Kitagawa et al., 2004), it 
is safe to conclude that c-Abl did not affect the generation of DSBs caused by 
adriamycin.  Adriamycin is also known to cause ssDNA in addition to DSBs.  I then 
tested whether c-Abl deficiency affected the foci formation for Atr.  As shown in (Fig. 
19E), there was no difference in the number of Atr foci between c-Abl-/- and control 
MEFs.  These results, taken together, indicate that c-Abl modulated the foci assembly of 
mediators such TopBP1, Brca1, 53BP1 and repair protein Rad51, but not MRN, Atm, 
Atr, or H2AX. 

























Figure 19. c-Abl-/- MEFs showed normal nuclear foci assembly of Mre11, Atm, phospho-
Atm (1981), H2AX, and Atr.  c-Abl-/- and control MEFs were treated with adriamycin for 
different periods of time and then immuno-stained for endogenous Mre11 (A), Atm (B), 
phospho-Atm (C), H2AX (D), and Atr (E), detected with Texas-red or FITC conjugated 
secondary antibodies.    
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5.II.3 downstream events of c-Abl under DNA damage 
5.II.3.1: Diminished activation of transducers Chk1 and Chk2 in c-Abl-/- 
cells 
The altered assembly of mediators and the normal assembly of Atm/Atr on 
nuclear foci suggest that co-localization of transducers and mediators might be disrupted 
in c-Abl-/- MEFs. This would affect the efficiency of signal propagation from Atm/Atr to 
effector molecules, as the function of the mediators is to recruit downstream targets to the 
signaling molecules. Two of the important targets are Chk1 and Chk2, which are 
phosphorylated by Atr and Atm respectively (Abraham, 2001b).  Adriamycin treatment 
resulted in activation of both Chk1 and Chk2, validated by Western blot using antibodies 
that only recognize activated Chk1 or Chk2 (Fig. 20A).  Activation of both Chk1 and 
Chk2 was dramatically reduced in c-Abl-/- MEFs, confirming that c-Abl is involved in 
activation of both Atm and Atr. This defect in Chk1/Chk2 phosphorylation can be 
explained by compromised activation of Atr/Atm, less effective recruitment of 
Chk1/Chk2 to Atr/Atm by adaptor proteins, or both.  I did observe a diminished Atm 
activation by adriamycin and an altered foci assembly of adaptor proteins in c-Abl-/- 
MEFs (Fig. 20B and Fig. 18). These data suggest that c-Abl is required for optimal 
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Figure 20.  c-Abl-/- MEFs showed diminished activation of Chk1/2 in response to 
adriamycin. A. c-Abl-/- and control MEFs were challenged with l µM of adriamycin for 
different periods of time and activation of Chk1 and Chk2 was analyzed with Western 
blot using antibodies that specifically recognize activated Chk1 or Chk2.  B. c-Abl-/- 
MEFs showed compromised phosphorylation of Atm in response to adriamycin. 
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5.II.3.2: Diminished activation of p53 in c-Abl-/- MEFs 
One important effector molecule downstream of Atm/Atr in DNA damage 
response is p53, which can be phosphorylated at Ser15 by Atm and Atr or at other sites 
such as Ser20 by Chk1/Chk2. p53 phosphorylation either enhances its transactivation 
ability or stabilizes the protein (Brooks and Gu, 2003). Ser 15 is an important residue in 
p53’s amino-terminal region and phosphorylation of p53 at this site signifies early 
response to a variety of genotoxic stresses (Banin et al. 1998; Canman et al. 1998). 
Phosphorylation at Ser15 may also be a critical event in the up-regulation and functional 
activation of p53 in response to DNA damage (Shieh et al.1997). 
Western blot analysis showed that p53 was evidently phosphorylated at Ser15, but 
not at Ser9, Ser20, or Ser496, and c-Abl deficiency led to a severely reduced Ser15 
phosphorylation in response to adriamycin (Fig. 21A), confirming that signaling from 
Atm/Atr was hindered.  These results indicate that c-Abl was required for an optimal 
signal transduction from Atm/Atr to p53 in response to adriamycin.   
p53 is a master gene in regulating DNA damage-induced cell cycle control at G1 
phase, apoptosis, and DNA repair (Lakin and Jackson, 1999). The diminished Ser15 
phosphorylation indicates that transactivation of p53 target genes might be affected.  
Indeed I found that adriamycin treatment led to a drastic induction of p21 at the protein 
level in control MEFs, but much less in c-Abl-/- MEFs (Fig. 21B). c-Abl deficiency 
similarly altered the induction of two other p53 targets 14-3-3σ and Gadd45 at the 
mRNA levels (Fig. 21C). These results further support the notion that c-Abl plays a 
critical role in DNA damage-induced p53 activation and likely downstream cellular 
events controlled by p53.  
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Figure 21. c-Abl-/- MEFs showed diminished p53 phosphorylation at Ser15, and 
compromised induction of p53 target genes in response to adriamycin. A. c-Abl-/- MEFs 
showed diminished p53 phosphorylation at Ser15 in response to adriamycin. The 
experiment was carried out as in Fig. 20A. B. c-Abl-/- MEFs showed compromised 
induction of p21 in response to adriamycin. C. Semi-quantitative RT-PCR assays show 
that induction of Gadd45 and 14-3-3σ mRNA in response to adriamycin was 
compromised in c-Abl-/- MEFs. 
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5.II.3.3: Evidence that c-Abl acts upstream of both Atm and Atr 
pathways  
Adriamycin was found to trigger a DNA-damage response through both Atm and 
Atr (Fig. 25A). To further confirm these observations, I subjected c-Abl-/- and control 
MEFs to genotoxic stress that activate either the Atm pathway or the Atr pathway. I first 
irradiated c-Abl-/- and control MEFs with IR (5Gy).  In the absence of c-Abl, both Chk2 
as well as p53 phosphorylation induced by IR were compromised (Fig. 22A & B).  c-Abl 
reconstitution rescued the defect in p53 phosphorylation (Fig. 22C). Furthermore, 
addition of STI571 to wild type MEFs, at a concentration (1 µM) sufficient to inhibit c-
Abl activation (Zeng et al., 2005), repressed p53 phosphorylation in MEFs (Fig. 22D).  
Notably the IR treatment did not dramatically alter the protein levels of p53 when 
compared with the extent of Ser15 phosphorylation. Neither was there a marked 
difference in p53 protein levels between c-Abl-/- and control MEFs.  These results suggest 
that IR induced p53 regulation mainly occurs at the level of phosphorylation rather than 
stabilization.  It has been previously reported that c-Abl interacts with and phosphorylates 
Mdm2, leading to p53 stabilization (Goldberg et al., 2002). Therefore, c-Abl may 
regulate p53 function through different mechanisms, depending on the experimental 
settings. Lastly, I confirmed that IR induced p53 phosphorylation at Ser15 required Atm, 
as Atm-/- MEFs showed significantly reduced phosphorylation at this site (Fig. 22E).  
These results indicate that c-Abl deficiency compromised the Atm dependent signaling 
pathway.  
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Figure 22. c-Abl-/- MEFs showed defects in IR-induced DNA damage response. A. c-Abl-
/- MEFs showed diminished activation of Chk2 in response to IR. c-Abl-/- and control 
MEFs were challenged with 5 Gy of IR and activation of Chk2 was analyzed at different 
time points after IR with Western blot. B. c-Abl-/- MEFs showed diminished p53 
phosphorylation at Ser15 in response to IR.  C. c-Abl reconstitution restored IR induced 
p53 phosphorylation to normal levels in c-Abl-/- MEFs. D. Inhibition of c-Abl with 
STI571 reduced IR-induced p53 phosphorylation. SB: SB203508, inhibitor of 
p38MAPK. WORT: Wortmannin, inhibitor of PIKK family members. E. Atm-/- MEFs 
showed compromised p53 phosphorylation in response to IR.  
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To confirm that diminished p53 phosphorylation reflects compromised activation, 
I analyzed p21 induction in response to IR.  It was found that c-Abl deficiency resulted in 
reduced induction of p21 (Fig. 28A), but not that of p16, p27 and CDK4, proteins 
involved in cell cycle entry but not under the control of p53 (Fig. 23A).  RT-PCR assays 
confirmed that c-Abl deficiency led to compromised induction of Gadd45 and 14-3-3σ in 
response to IR (Fig. 23B). These results confirmed that c-Abl is required for proper 
activation of p53. 
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Figure 23. c-Abl-/- MEFs showed defects in IR-induced DNA damage response.  A. c-
Abl-/- MEFs showed compromised induction of p21, but not p27, p16, or CDK4, in 
response to IR. B. Semi-quantitative RT-PCR assays show that c-Abl-/- MEFs showed 
compromised induction of Gadd45 and 14-3-3σ in response to IR, which could be 
rescued by c-Abl reconstitution. 
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To verify my hypothesis that c-Abl acts upstream of ATM/ATR pathway, I 
activated ATR with external chemotherapeutic agents that were well-known to activate 
only the ATR pathway. Even though evidence indicates that ATR phosphorylates an 
overlapping set of target genes to ATM, but it responds to a distinct spectrum of lesions 
from those that trigger ATM activation (Cobb et al., 2005; Shinozaki et al., 2003). DNA 
synthesis blockade drugs HU and APH are used in my experiments. HU serves to prevent 
entry into S-phase, while APH serves to slow down the progress through S-phase in 
dividing cells (Shechter et al., 2004; Hatse et al., 1999).  
To test whether c-Abl is involved in the Atr pathway, c-Abl-/- and control MEFs 
were treated with HU or APH. Inhibition of the PIKKs by wortmannin or caffeine 
blocked HU induced Ser15 phosphorylation of p53, confirming that PIKKs were required 
for it (Fig. 24A).  I also confirmed that Atm deficiency did not affect HU or APH induced 
p53 phosphorylation at Ser15. However, c-Abl-/- MEFs showed a diminished Chk1 
phosphorylation and a compromised p53 phosphorylation in response to either HU or 
APH treatment (Fig. 24B & C). These results demonstrated that c-Abl has an influence 
on Atr signaling in addition to Atm. This was confirmed by the observation that 
inhibition of c-Abl with STI571 diminished HU induced p53 phosphorylation in MEFs 
and that c-Abl-/- osteoblasts also showed compromised p53 phosphorylation in response 
to HU (Fig. 24D &E).  Taken together, these results indicate that c-Abl is involved in 
both DSBs triggered Atm pathway and in ssDNA triggered Atr pathway and that c-Abl is 
likely to act upstream of Atm/Atr.  
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Figure 24. c-Abl participates in Atr-dependent DNA damage response. A. Inhibition of 
PIKKs with wortmannin (WORT, upper panel) or caffeine (lower panel) blocked HU-
induced p53 phosphorylation. PD, PD98059, an ERK specific inhibitor (10uM); SB, 
SB203580, a p38 MAPK inhibitor (10 µM), ROTT, rottlerin, a PKC delta inhibitor (1 
µM).  Cells were pretreated with different inhibitors for 2 hours before HU was added to 
the cultures. B. c-Abl-/- MEFs showed diminished activation of Chk1 in response to 
aphidicolin. c-Abl-/- and control MEFs were challenged with different doses of 
aphidicolin or IR and activation of Chk1 was analyzed with Western blot. C. c-Abl-/- 
MEFs showed compromised p53 phosphorylation in response to HU, APH, and cisplatin 
(CDDP).
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Figure 24. c-Abl participates in Atr-dependent DNA damage response. D. Inhibition of 
c-Abl with STI571 reduced HU-induced p53 phosphorylation in MEFs. The experiment 
was carried as described in Fig. 24A except that STI571 was used. E. c-Abl deficient 
osteoblasts also showed reduced HU-induced p53 phosphorylation.  
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5.II.4 Involvement of c-Abl in DNA damage induced cell cycle control 
and DNA repair 
5.II.4.1: The effect of c-Abl deficiency on adriamycin-induced apoptosis 
I first wanted to confirm the pro-apoptotic role for c-Abl in response to 
adriamycin by measuring cell death rates using trypan blue exclusion method, and cell 
survival rates with WST-1 assay. Treatment with 1 or 5 µM of adriamycin did not cause 
significant cell death in either c-Abl-/- or control MEFs, even though p53 phosphorylation, 
Chk1/2 activation and up-regulation of p53 target genes were readily detectable at 1uM 
of adriamycin.  Under this condition, the levels of apoptotic related proteins did not show 
significant up-regulation, including p53 target genes Bax and Bcl2 (Fig. 25A). More 
interestingly, adriamycin induced p21 expression at 1uM but not at 10 µM in normal 
MEFs (Fig. 25B). These results suggest that p53 could differentially regulate 
transcription of its target genes in response to different stress conditions, as previously 
reported (Barlow et al., 1997). This could be addressed by other types of modification on 
p53 (Brooks and Gu, 2003). At a higher concentration (10 µM), adriamycin could cause 
cell death.  Even so, no significant difference in cell death rates was detected between c-
Abl-/- and control MEFs (Fig. 25C). These results clearly show that c-Abl does not play a 
major role in adriamycin-induced apoptosis. Similarly, 5 Gy or 15 Gy of IR did not cause 
significant cell death in c-Abl-/- or control MEFs, indicating that under this experimental 
setting, the main response to IR or adriamycin of primary MEFs is not apoptosis but cell 
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Figure 25. c-Abl-/- MEFs does not show significant defects in DNA damage induced 
apoptosis. A. Adriamycin does not significantly induce apoptosis related genes. c-Abl-/- 
and control MEFs were challenged with 1uM of adriamycin for different periods of time 
and the protein levels of apoptosis related genes were determined by Western blot 
analysis. B. high dose of adriamycin does not induce p21 expression. c-Abl-/- and control 
MEFs were challenged with 1 or 10 µM adriamycin for different periods of time and the 
protein levels of p21 were determined by Western blot. C. c-Abl does not affect 
adriamycin induced cell death.  c-Abl-/- and control MEFs were challenged with 10 µM 
adriamycin for different periods of time and the cell death rates were determined by 
trypan blue exclusion (n=4). 
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5.II.4.2: The effect of c-Abl deficiency on adriamycin-induced cell cycle 
control 
I next checked the cell cycle checkpoints imposed by DNA damage in c-Abl-/- 
MEFs: G1 to S, intra-S, and G2/M.  p53 controls G1/S checkpoint and Chk1/ and Chk2 
are involved in all three checkpoints (Brooks and Gu, 2003). A defect in both Chk1/and 
Chk2 activation suggested that all three checkpoints would be affected in c-Abl-/- cells 
(Abraham, 2001c). I used various techniques to study cell cycle progression. Flow 
cytometry analysis with propidium iodide (PI) staining of IR-treated c-Abl-/- and control 
MEFs was first carried out. PI staining showed that about 42% of untreated wild type or 
c-Abl-/- MEFs were in S/G2/M phase. Eight hours after IR (5 Gy), most of the normal 
cells were arrested at the G1 phase and only 20% of cells were in S/G2/M phase.  
However, c-Abl-/- MEF cultures had 37% cells in S/G2/M (Fig. 26), suggesting defective 
cell cycle checkpoints.   
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Figure 26. c-Abl-/- MEFs showed a defect in cell cycle control. c-Abl-/- and control MEFs 
were challenged with 5 Gy of IR and cell cycle profiles were analyzed by FACS after PI 
staining. Left: the FACS profile; Right: the quantitation data 
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Secondly, radio-resistant DNA synthesis (RDS) assay was used to check the 
effect of c-Abl on intra-S checkpoint control. The initial labeling of DNA with 14C 
measures the amount of starting DNA material in cells and following labeling of 3H after 
IR exposure measures the newly synthesized DNA. I also observed increased RDS in c-
Abl-/- MEFs in response to IR (Fig. 27), confirming a defective intra-S checkpoint. 
Moreover, a higher ratio of 3H to 14C is consistently observed in c-Abl-/- MEF cells under 










































      
 
 
Figure 27. c-Abl-/- MEFs showed more RDS in response to IR. c-Abl-/- and control MEFs 
were challenged with 5 Gy of IR and cell cycle profiles were analyzed by RDS assay. 
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Thirdly, a specific antibody phospho-histone H3 was able to stain cells at the 
G2/M phase and the intensity can be similarly measured by flow cytometry, but at a 
different emission wavelength from PI staining (Fig. 28A). c-Abl-/- MEF cultures showed 
more cells in G2/M phase after IR treatment, justified by an increased number of 
phospho-H3 positive cells and an increase in the amount of phospho-H3 protein on a 
Western blot (Fig. 28B).  c-Abl-/- MEFs displayed a similar response to adriamycin as IR 
(data not shown). These results indicate that c-Abl plays a critical role in an early step of 
the DNA damage response and it regulates all checkpoints.   
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Figure 28. c-Abl-/- MEFs showed defects in DNA damage induced G2/M checkpoint. A. 
Staining of cells in different phases of the cell cycle with the phospho-histone H3 
antibody. B. c-Abl-/- MEFs showed more cells in the mitotic phase after IR.  Upper panel: 
percentage of cells positive for phospho-H3; lower panel: Western blot shows increased 
amounts of phospho-H3 protein in c-Abl-/- MEFs.   
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5.II.4.3: c-Abl deficiency led to defects in DNA repair 
The observation that c-Abl deficiency led to altered Rad51 and Brca1 foci 
localization, prolonged manifestation of foci, and compromised phosphorylation of p53 
prompted us to examine a possible role for c-Abl in DNA damage repair.   
Two experiments were carried out to measure DNA repair. Firstly, the comet 
assay, also called the 'Single Cell Gel Assay', is the technique to detect DNA damage and 
repair at the level of single cells. During electrophoresis, broken DNA fragments 
(damaged DNA) or relaxed chromatin migrates away from the nucleus. The extent of 
DNA liberated from the head of the comet was directly proportional to the DNA damage.  
This single cell electrophoresis method is used to quantify DSBs or ssDNA.  
Three pairs of c-Abl-/- MEF cells were tested and they consistently showed a significant 
increase in total DNA damages from the alkaline electrophoresis of the cells in the Comet 
assay. This condition detects all kinds of DNA damages including both SSBs and DSBs. 
However, neutral electrophoresis of the cells did not reveal significant difference between 
c-Abl-/- MEF cells from control cells, an indication that the amount of DSBs generated in 
c-Abl-/- MEFs is comparable to that of wild type cells. This indirectly suggests that c-Abl-
/- cells generated more SSBs under IR exposure of the cells or DSBs are quickly 
converted to SSDNA. c-Abl-/- and control MEFs were irradiated with 2.5Gy of IR and the 
cells were collected for comet assays, at 0.5 or 24 hrs after IR.  It was observed that c-
Abl-/- MEFs showed significantly more SSBs, but not DSBs (Fig. 29A and B).  This is 
consistent with the observation that c-Abl-/- cells exhibited the same number of H2AX 
foci as control cells (Fig. 19D).  These results indicate that c-Abl deficiency causes a 
defect in DNA repair, likely at steps involving single stranded DNA.  This may explain 
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why c-Abl-/- MEFs showed sustained manifestation of DNA damage induced foci at a 





















































0   0.5  24 0   0.5  24 

























Figure 29. DNA repair defects in c-Abl-/- MEFs. A. c-Abl-/- MEFs showed increased 
amounts of ssDNA. c-Abl-/- and control MEFs were challenged with IR, collected at 0.5 
or 24 hours after IR, and used for comet assay at alkaline pH. B. c-Abl-/- MEFs showed a 
normal level of DSBs. The experiment was carried out as in Fig. 36A except that comet 
assay was done at neutral pH.   
 
Another quantitative experiment confirmed the result. Under certain conditions 
when DNA is assaulted, they develop simple base changes, or more complex ones 
including deletions, fusions, translocations or aneuploidy. I then tested the amount of 
DNA damages generated in c-Abl-/- cells using a commercial kit that measures 
Apurinic/apyrimidinic (AP) sites. The level of AP sites in cells can be a good indicator of 
DNA lesion and repair against chemical damage and cell aging. There could be several 
thousand bases spontaneously lost within a typical mammalian cell per day. c-Abl-/- 
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MEFs had more Apurinic/apyrimidinic (AP) sites than control cells at 8 or 24 hours after 
adriamycin treatment (Fig. 30A), or 8 hours after IR treatment at 5Gy (Fig. 30B). 
However, there is no significant difference in the amount of protein, APE-1/REF-1, an 
enzyme that removes AP sites (Evans et al., 2000) (Fig. 30C). All these results indicate 
that c-Abl effects the repair of damaged DNA. 
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Figure 30. DNA repair defects in c-Abl-/- MEFs. A. c-Abl-/- MEFs showed increased 
amounts of AP sites in response to IR. The experiment was carried out as in Fig. 29A 
except AP sites were measured. B. c-Abl-/- MEFs showed increased amounts of AP sites 
in response to adriamycin treatment.  The experiment was carried out as in Fig. 29A 
except adriamycin was used (n=4). C. c-Abl-/- and control MEFs were challenged with 
1uM Adriamycin, collected at different time points and analyzed by western blotting for 
the antibody APE-1/REF-1. * Significant when compared to control cells under the same 
conditions. 
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Chapter 6: Conclusion and General 
discussion to Result Part II 
6.1: Examination of c-Abl in DNA damage responses 
Previous studies show that c-Abl is involved in DNA damage response.  It is 
activated by DSBs in an Atm dependent manner and its main role is to relay the pro-
apoptotic signal from Atm to p73 or p53 by stabilizing these pro-apoptotic proteins. My 
current studies confirmed a role for c-Abl in DNA damage response, at an additional step 
undiscovered by previous studies. I found that c-Abl deficiency results in abnormal 
nuclear foci formation of adaptor and repair proteins, compromised 
phosphorylation/activation of Atm/Atr targets p53, Chk1 and Chk2, compromised 
induction of p53 target genes such as p21, 14-3-3σ, defective cell cycle control, and 
compromised DNA repair. Therefore many aspects of the DNA damage response were 
altered in c-Abl deficient cells, suggesting that c-Abl acts at a much earlier step, likely at 
the assembly of nuclear foci, centers for DNA repair and signaling.   
My results indicate that c-Abl plays an important role in DNA damage response 
pathways involving both Atm and Atr.  Adriamycin was found to produce both DSB, 
which activated Atm and Chk2, and ssDNA, which activated Atr and Chk1. Both Atm 
and Atr were found to localize to nuclear foci in the presence of adriamycin. More 
importantly, I found that c-Abl deficiency led to compromised activation of both Atm and 
Atr, manifested by compromised activation of Chk2/Chk1 and p53 phosphorylation at 
Ser15. This is confirmed by the observation that c-Abl deficiency results in compromised 
activation of Chk2 and p53 in response to IR that activates the ATM pathway, and 
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compromised activation of Chk1 and p53 in response to hydroxyurea and aphidicolin that 
turns on the ATR pathway.  Based on the dynamics of DSB repair, I believe that the role 
for c-Abl in adriamycin induced DNA damage mainly targets at ssDNA, which could be 
generated either by direct effects of adriamycin or by resection of the DSBs.  This is 
supported by the following observations.  First, the difference in the number of foci 
between c-Abl-/- and control cells becomes more evident at later time points of 
adriamycin treatment, at least 8 hrs or longer, and the foci were manifested for an 
extended time in c-Abl-/- cells, indicating a defect in the slow repair process (HRR).  
Secondly, these foci were positive for Brca1 and Rad51, proteins involved in HRR.  It 
has been reported that IR induced SSB foci co-localize with Rad51 (Raderschall et al., 
1999). Thirdly, c-Abl-/- cells accumulated an increased number of ssDNA breaks, but 
comparable numbers of DSBs compared with control cells.  This conclusion is further 
supported by the fact that the number of H2AX positive foci that correlates with the 
number of DSBs was not altered in c-Abl-/- cells. This impaired HRR is in accordance 
with the dysfunctional assembly of the foci. Fourthly, a study on BCR-ABL in DNA 
damage response indicates that BCR-ABL, active form of c-Abl  regulates Atr activation 
by translocating into the nucleus and results in an intra-S checkpoint defect mediated 
through ATR-dependent signaling (Dierov et al., 2004).   
6.2: c-Abl acts upstream of ATM/ATR 
Another important conclusion from my studies is that c-Abl appears to act 
upstream of Atm and Atr, as c-Abl deficiency results in compromised activation of Atm 
and diminished activation of the direct targets of Atm or Atr, Chk1, Chk2 and p53.  
Based on my and others’ findings, I believe that there are at least two possibilities by 
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which c-Abl regulates Atm/Atr activity.  One is through tyrosine phosphorylation, as c-
Abl has been reported to interact with Atm and BCR-ABL has been found to interact 
with Atr (Dierov et al., 2004; Shafman et al., 1997). The interaction might result in 
tyrosine phosphorylation of Atm and Atr, facilitating their activation.  The other 
possibility is to regulate the colocalization of Atm/Atr kinases with the mediators/effector 
molecules. c-Abl deficiency clearly altered foci localization of TopBP1, 53BP1, and 
Brca1, but not H2AX, Atm or Atr. This aberrant assembly of signal transducers and 
mediators might disrupt signal propagation from Atm/Atr to downstream targets such as 
Chk1/Chk2 and p53.  This notion is supported by the observation that both 53BP1 and 
Brca1 are required for optimal phosphorylation of downstream targets by Atm and Atr 
and that 53BP1 is also required for optimal activation of Atm (Rappold et al., 2001; 
Foray et al., 2003; Mochan et al., 2003).  It is also possible that both mechanisms play 
important and overlapping roles in signal transmission. Still the molecular mechanisms of 
c-Abl function warrant further investigation. Nevertheless, these results clearly indicate 
that c-Abl regulates Atm/Atr activation in a direct or indirect way. Since c-Abl activation 
requires Atm, a positive feedback loop might exist in which Atm activated c-Abl 
facilitates the proper recruitment of adaptors and repair proteins to the nuclear foci and/or 
the activation of Atm/Atr. 
6.3: c-Abl may relay signals from DSBs to ssDNA response 
DSBs can be repaired by NHEJ, a rapid process involving DNA-PKcs and 
Ku70/80 proteins, or by HRR, a slower process involving Brca1 and Rad51 and requiring 
DNA replication. ssDNA is generated during the initial repair process of DSBs and is 
required for HRR. This is supported by the evidence that the catalytic subunit of DNA-
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PK, an essential component in NHEJ, has affinity for single-stranded DNA ends derived 
from a DSB. The binding of DNA-PKcs to such a region activates this serine/threonine 
protein kinase, which in turn phosphorylates other proteins such as XRCC4 involved in 
NHEJ. Furthermore, Mre11-Rad50-Nbs1 (MRN), the key component of both NHEJ and 
HRR pathways, was known to be involved in processing the DNA ends at DSBs prior to 
religation in NHEJ and in DNA end-resection to create single strand DNA ends prior to 
homologous pairing and strand invasion in HRR. Moreover, genetic studies in yeast 
report that Mre11, the same component of the MRN complex in mammals, regulates the 
5' to 3' exonuclease that is responsible for resection of the 5' ends of DSBs prior to single-
strand annealing. γ-H2AX, a downstream target of ATM/ATR, helps to recruit a 
chromatin remodeling complex, which facilitates the resection of 5'-terminated strands at 
DSBs by exonuclease, and ssDNA is generated as a result. All these studies provide 
evidence for the requisite of ssDNA generation from DSBs. Furthermore, NHEJ and 
HRR act in cooperative and complementary ways to repair DSBs, mice cells deficient in 
XRCC2 or XRCC3, proteins for NHEJ have reduced rates of HRR and higher levels of 
chromosomal aberrations. Cells lacking both Rad54 and Ku proteins have greater 
radiosensitivity than those with a single mutation (Essers et al., 1997; Pierce et al., 1999; 
Liu et al., 1998). 
Here, I propose a model for c-Abl action in response to DSBs based on my results 
and that of others. Once DSBs occur, Atm is localized onto DSBs and activated in a 
MRN complex dependent manner.  Atm further activates its interacting protein c-Abl 
through phosphorylation. At the same time, ssDNA is generated by resection of the 
DSBs, followed by assembly of Atr and associated proteins at these sites. Activated c-
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Abl might phosphorylate adaptor proteins or Atm/Atr, which interact with c-Abl, 
facilitating the optimal activation of Atm/Atr. Without c-Abl, these adaptor proteins are 
mislocalized, activation of Atm/Atr is impaired, and activation of downstream molecules 
is compromised. Therefore, c-Abl may function to relay signals from DSB response to 
ssDNA response and c-Abl acts at a very early step in DNA damage responses. Previous 
reports also suggested that c-Abl may act at the initiation of the two DSBs repair 
mechanisms. c-Abl phosphorylates DNA-PK and reduces NHEJ repair by dissociating 
the DNA-PKcs-Ku70/80 trimeric protein from DNA. c-Abl was also known to dissociate 
from BRCA1 in HRR under IR exposure.  
6.4: c-Abl function involves p53 
My results also indicate that the c-Abl’s function in DNA damage response 
involves p53.  Previous studies have shown that c-Abl controls the expression of p53 by 
interacting with and modifying Mdm2 (Goldberg et al., 2002).  DNA damage-induced 
activation of c-Abl leads to Mdm2 tyrosine phosphorylation, which disrupts the 
interaction between Mdm2 and p53, and stabilizes p53. In my experimental settings, the 
increase in p53 protein levels is much less than that of Ser15 phosphorylation, and Ser15 
phosphorylation correlates well with induction of p53 target genes such as p21, Gadd45, 
and 14-3-3.  These results suggest that c-Abl can regulate the activation of p53 via 
Atm/Atr and that Ser15 phosphorylation and subsequent activation of p53 plays an 
important role in response to adriamycin and IR treatments. 
Although p53 activation can induce apoptosis and cell cycle arrest, I observed that 
the main response of primary MEFs to IR or adriamycin is cell cycle arrest rather than 
apoptosis. Adriamycin or IR, at a dose (up to 5uM or 15 Gy respectively) sufficient to 
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activate Chk1/Chk2 and p53, neither up-regulated apoptosis-promoting proteins nor 
induced significant cell death. Only at much higher levels of genotoxic stress, did the 
cells show marked cell death. However no significant difference in cell death rates was 
observed between c-Abl-/- and control cells, suggesting a minimal effect for c-Abl in 
DNA damage induced apoptosis.  On the contrary, c-Abl-/- MEFs did show defects in cell 
cycle control, as cell cycle analysis, radio-resistant DNA synthesis, and H3 
phosphorylation experiments clearly demonstrated that more c-Abl-/- MEFs could enter 
cell cycle in the presence of adriamycin or IR.  This is consistent with the compromised 
p53 activation and diminished activation of Chk1 and Chk2.  The discrepancy between 
these results and previous reports could be caused by the difference in genetic 
background of mice (C57BL/6 in this study), the passage of the MEFs (early passage and 
unimmortalized cells in this study), or controls used (MEFs from control littermates in 
this study).   
6.5: A novel role for c-Abl in DNA repair                     
Some previous reports even suggest that c-Abl is not essential in genome 
maintenance as c-Abl-/- cells did not show hypersensitivity to IR. ATM-/- cells are highly 
responsive to spontaneous and radiation-induced chromosomal aberrations. However, 
double compound c-Abl/Atm-/- cells from a chicken B lymphocyte DT40 cell line did not 
aggravate ATM-related defects of cellular response to radiation, suggesting the same 
hypothesis (Takao et al., 2000). Here, my results suggested a crucial role for c-Abl in 
DNA repair.  
c-Abl-/- MEFs exhibited a normal number of H2AX positive nuclear foci and the 
comet assay revealed no significant difference in the number of DSBs.  However, they 
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accumulate an increased numbers of ssDNA and AP sites.  AP sites can be generated next 
to IR–induced DSBs and cleavage of the AP sites by APE converts them to ssDNA for 
initiation of repair (Datta et al., 2005; Boiteux and guillet, 2004; Wilson and Barsky, 
2001). These results suggest that c-Abl deficiency has a more prominent effect at a step 
of DNA repair involving ssDNA, generated by resection of DSBs or other means. One 
possible mechanism is that c-Abl deficiency disrupted the proper assembly of foci 
proteins e.g., Brca1, Rad51, at the sites of DNA lesions. Another possibility is that 
modification of Brca1 and Rad51 by c-Abl might facilitate HRR (Foray et al., 2002; 
Yuan et al., 1998; Chen et al., 1999). Differential DNA repair of removal of UV-
generated pyrimidine dimers was observed in c-Abl and c-Mos proto-oncogenes, with the 
c-Abl gene capable of removing more dimers within 24hr (Hanawalt, 1989; Madhani et 
al., 1986). Tyrosine phosphorylation of Rad51 by c-Abl is also known to enhance the 
complex formation between Rad51 and Rad52, probably facilitating HRR or even 
helping in making the cellular choice of choosing HRR over NHEJ.  
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In summary, my findings place c-Abl action at a novel step in the DNA damage 
response.  It forms a feedback loop with Atm to regulate DNA damage induced nuclear 
foci formation, cell signaling from the foci to effector molecules, cell cycle checkpoints 
and DNA repair. Moreover, c-Abl also participates in ssDNA triggered Atr pathway 
(Illustration 8). 
 
















Illustration 8: A proposed feedback loop between Atm and c-Abl in DNA damage 
response. m, Mre11; r, Rad50; n, NBS1, B, Brca1; 53, 53BP1; T, TopBP1. In response to 
DSBs, Atm is activated and it activates c-Abl.  c-Abl then regulates nuclear foci 
formation of Brca1, TopBP1 and 53BP1, and enhances the activation of Atm and Atr, 
which is located to ssDNA generated by resection of DSBs. Both Atm and Atr 
incorporate positive signals from c-Abl to regulate checkpoints or DNA repair via Chk2, 
Chk1, and p53. 
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Chapter 7: OVERALL PERSPECTIVE 
7.1 CONCLUSION 
I identified p53 as a novel regulator of osteoblast differentiation, osteoblast-
dependent osteoclastogenesis and bone remodeling. p53-/- mice display a high bone mass 
phenotype and p53-/- osteoblasts show accelerated differentiation secondary to an 
increase in expression of the osteoblast differentiation factor osterix as a result. Reporter 
assays indicate that p53 represses osterix transcription by the minimal promoter in a 
DNA-binding independent manner. In addition, p53-/- osteoblasts have an enhanced 
ability to favor osteoclast differentiation, in association with an increase in expression of 
M-CSF, which is under the control of osterix.  Furthermore, inactivating p53 is sufficient 
to rescue the osteoblast differentiation defects observed in mice lacking c-Abl, a p53 
interacting protein.   
Meanwhile, I provided evidence that c-Abl acts at a novel step that affects most 
cellular events in DNA damage response. c-Abl-/- MEFs showed defects in nuclear foci 
assembly of proteins such as TopBP1, Brca1, 53BP1 and Rad51, activation of both Chk2 
and Chk1, phosphorylation of p53 at Ser15 and induction of p53 target genes, cell cycle 
checkpoints and DNA repair of single stranded DNA breaks. I also indicated that c-Abl 
functions upstream of Atm and Atr in response to DSBs and ssDNA.  Therefore, I 
propose a feedback loop in which Atm activated c-Abl supports proper nuclear foci 
formation and Atm/Atr activation to regulate cell cycle control and DNA repair. 
7.2 DISCUSSION 
p53 is a well known tumour suppressor and is called the “guardian of the 
genome” for it’s role in maintaining the integrity of DNA (Carr, 2000). Essential roles of 
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p53 in cellular function of death and survival has been well and intensively studied, 
however, research on the role of such an important protein in animal and human 
development has just begun. My studies have certainly provided new insights into 
developmental functions of tumour suppressor genes like p53 and offered clues for a 
better understanding of different roles played by this master regulator protein.  
Another example of such proteins is c-Abl, which is a proto-oncogene. Similarly 
to p53, c-Abl is also involved in various cellular events ranging from DNA 
recombination to DNA repair (Li, 2005). c-Abl was also found to play a vital role in 
mouse development, especially in bone development and in that of the immune system 
(Chung and Wong, 1995).  
From these possible links, it would be worthwhile to further investigate the roles 
of other proto-oncogenes and tumour suppressors in animal development, as alluded by 
the discussion for the participation of cellular oncogenes in normal developmental 
processes (Muller et al., 1982). It has been reported that stage- and tissue-specific 
expressions of cellular oncogenes are different during mouse pre-natal and early post-
natal development, indicating their distinct roles at different stages of animal 
development. Therefore, studies of the mechanisms of a particular protein in 
development may lead to answers to questions like how tumour suppressors or 
oncogenes, important for tumorigenesis, are expressed at different levels in an organism 
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